

<b>A Method for Preparing Modified Polypeptides</b>
---

5

**FIELD OF THE INVENTION**

The present invention relates to methods for improving properties of a polypeptide of interest, in particular for altering the immunogenicity and/or increasing the functional *in vivo* half-life of a polypeptide of interest.

**BACKGROUND OF THE INVENTION**

Polypeptides, including proteins, are used for a wide range of applications, including industrial uses and therapeutic applications. A known drawback associated with the use of polypeptides for applications involving contact with humans or animals is that the polypeptides often give rise to an immune response.

Attempts have been made to reduce the immunogenicity and/or allergenicity of polypeptides. One of the most widespread strategies has been to shield epitopes of the polypeptide (which give rise to the undesired immune or allergic response) with polymer molecules, such as polyethylene glycol (PEG), conjugated to the polypeptide. The conjugation of the PEG polymer to a polypeptide is often termed PEGylation. An example of this is disclosed in US 5,856,451 wherein modified polypeptides with reduced allergenicity are disclosed, which polypeptides comprises a parent polypeptide with a molecular weight in the range of 10-100 KDa conjugated to a polymer with a molecular weight in the range of 1-60 KDa. It is stated that the polypeptide to be modified may be a variant of a parent enzyme that has additional attachment groups, such as amino groups not present in the parental enzyme. WO 96/40792 discloses a specific method of PEGylating proteins with a view to reducing allergenicity and/or immunogenicity. WO 97/30148 discloses a method of reducing allergenicity of a protein, wherein the protein is conjugated to at least two polymer molecules. It has been suggested to selectively modify PEGylation attachment groups of polypeptides to be PEGylated. For instance, WO 98/35026 discloses polypeptide-polymer conjugates that have added and/or removed one

or more selected attachment groups for coupling polymer molecules on the surface of the three dimensional structure of the polypeptide. By use of site-directed mutagenesis it is suggested to add attachment groups for the polymer molecules at predetermined locations of the polypeptide surface in an attempt to increase the number of polymer molecules, 5 which may be attached and/or to remove attachment groups at or close to the active site of the polypeptide allegedly to avoid excessive PEGylation near the active site, which may lead to decreased activity of the polypeptide.

Another method of modifying polypeptides is disclosed in WO 92/10755 in which it has been suggested to reduce the allergenicity of proteins by identification of epitopes 10 and subsequent destruction of the epitope by modification of amino acid residues constituting the epitope.

US 5,218,092 discloses polypeptides with at least one new or additional carbohydrate attached thereto, the polypeptides allegedly having increased stability as compared to the corresponding unmodified polypeptide. The additional carbohydrate 15 molecule(s) is/are provided by adding one or more additional N-glycosylation sites to the polypeptide backbone, and expressing the polypeptide in a glycosylating host cell. WO 00/26354 discloses a method of reducing allergenicity of proteins, in particular enzymes, wherein the reduction in allergenicity is mediated by increasing the glycosylation of the protein through one or more additional glycosylation sites.

20 Apart from giving rise to an immune response a further known disadvantage associated with the use of polypeptide-based drugs is that these drugs often are rapidly degraded or eliminated in the body. It has been reported that conjugation of the polypeptide with polymer molecules may increase the functional *in vivo* half-life. For instance US 4,935,465 discloses a prolonged clearance time of a PEGylated polypeptide 25 due to the increased size of the PEG conjugate of the polypeptide in question.

WO 98/48837 relates to single-chain antigen-binding polypeptide-polyalkylene oxide conjugates with reduced antigenicity and increased half-life in the blood stream. The single chain antigen-binding polypeptide to be modified may include one or more inserted Cys or Lys capable of polyalkylene oxide conjugation at certain predetermined sites. 30 Delgado et al., Critical Reviews in Therapeutic Drug Carrier Systems, 9(3,4): 249-304 (1992) is a review article disclosing the state of the art in relation to the uses and properties of PEG-linked polypeptides.

WO 96/12505 discloses conjugates of a polypeptide with a low molecular weight lipophilic compound, which are reported to have improved pharmacological properties.

It has been reported that PEGylation of polypeptides may result in reduced function of the polypeptide. Shielding the active site of the polypeptide during PEGylation has been suggested in an attempt to avoid this reduction in activity. More specifically, WO 94/13322 discloses a process for the preparation of a conjugate between a polymer and a first substance having a biological activity mediated by a domain thereof, wherein, during conjugation, the domain of the first substance is protected by a second substance which is removed after conjugation has taken place. It is stated that by using the method the biological activity of the first substance is fully preserved in contrast to the conventional conjugation processes, which normally lead to polymer conjugates with reduced biological activity.

WO 93/15189 relates to a method of preparing proteolytic enzyme-PEG adducts in which the proteolytic enzyme is linked to a macromolecularised inhibitor when reacted with PEG so as to block the active site of the enzyme and thereby preventing that PEG is bound at or near the active site.

WO 97/11957 discloses a process for improving the *in vivo* function of a polypeptide, in particular factor VIII, by shielding exposed targets of said polypeptide, in which method the polypeptide is immobilized by interaction with a group-specific adsorbent carrying ligands manufactured by organic-chemical synthesis, a biocompatible polymer is activated and conjugated to the immobilized polypeptide and the conjugate is eluted from the adsorbent.

WO97/47751 discloses various forms for modification of a DNase, e.g. by conjugation to a polymer, a sugar moiety or an organic derivatizing agent. WO 99/40198 discloses various staphylokinase variants modified so as to result in reduced immunogenicity. US 4,904,584 discloses PEGylated lysine depleted polypeptides, wherein at least one lysine residue has been deleted or replaced with any other amino acid residue. WO 99/67291 discloses a process for conjugating a protein with PEG, wherein at least one amino acid residue on the protein is deleted and the protein is contacted with PEG under conditions sufficient to conjugate the PEG to the protein. WO 99/03887 discloses PEGylated variants of polypeptides belonging to the growth hormone superfamily, wherein a cysteine residue has been substituted for a non-essential amino acid residue located in a specified region of the polypeptide.

All of the above described prior art methods are based on using a directed mutagenesis approach to modify polypeptides of interest. Using such site directed mutagenesis techniques, polymer attachment groups are added or removed, thereby

enabling construction of polypeptide-polymer conjugates wherein the polymer molecules are attached at certain predetermined locations, typically at the surface of the polypeptide to be modified.

WO 98/27230 discloses the use of shuffling techniques for modifying proteins.

- 5 The present invention elucidates further methods for modifying polypeptides of interest to have polymer attachment sites that improve one or more functional aspect of the polypeptide.

## BRIEF DISCLOSURE OF THE INVENTION

10

Rather than introducing attachment groups at predetermined locations at the surface of the polypeptide to be modified, the present invention involves the intelligent creation of diversity in combination with a high throughput screening system.

- Accordingly, in a first aspect, the invention relates to a method for altering, i.e.,  
15 reducing or increasing, the immunogenicity and/or increasing the stability, e.g., functional *in vivo* half-life, of a polypeptide of interest while maintaining a measurable function of the polypeptide. Such method involves, a) selecting a region of the nucleotide sequence encoding the polypeptide, b) diversifying the selected region, c) expressing the polypeptides encoded by the diversified population of nucleotide sequences, d)  
20 conjugating a non-polypeptide moiety to the expressed polypeptides, and e) selecting polypeptide conjugates with altered immunogenicity and/or increased stability.

- In some embodiments, the region is selected by computer assisted modeling based on the primary and/or tertiary structure of the polypeptide, e.g. as out-lined in further detail in the section entitled "Strategies for preparing a diversified population of  
25 nucleotide sequences". In some embodiments, diversification is achieved by one or more of DNA shuffling, random mutagenesis, focused mutagenesis, and localized mutagenesis. In some cases, the diversification process involves doping or spiking with oligonucleotides. Optionally, the diversification process is performed recursively. If desired, one or more such diversified nucleotide sequence is further modified by site  
30 specific mutagenesis.

In some embodiments, the diversified population of nucleotide sequences includes sequences with altered numbers of codons encoding amino acid residues capable of functioning as attachment groups for non-polypeptide moieties such as sugar moieties, lipophilic molecules, polymer molecules, or organic derivatizing agents.

In preferred embodiments, polynucleotide sequences encoding polypeptides with altered immunogenicity and/or increased stability are identified by a high throughput screening method. For example, a screening assay performed in microtiter plates, on one or more filters or membranes, or pin or bead array, or in a microfluidic device.

5 Another aspect of the invention relates to the production of polypeptides with altered glycosylation patterns having desired properties. In a general embodiment, methods involve a) expressing a diversified population of nucleotide sequences encoding a polypeptide of interest, b) glycosylating the expressed polypeptides, and c) selecting at least one polypeptide with a desired property.

10 In some embodiments, the population of nucleotide sequences is produced by one or more of DNA shuffling, random mutagenesis, focused mutagenesis, localized mutagenesis, and site specific mutagenesis. In preferred embodiments, the population of nucleotide sequences so produced includes nucleotide sequences encoding polypeptides with altered numbers or locations of glycosylation sites.

15 Nucleotide sequences encoding polypeptides with desired properties are identified by high throughput screening assays in some embodiments. In some embodiments, the desired property is selected from reduced or increased immunogenicity or increased stability, e.g., increased functional *in vivo* half-life.

In another aspect, the invention provides methods for altering immunogenicity or  
20 improving stability of a polypeptide by a) expressing a diversified population of nucleotide sequences encoding a polypeptide of interest, b) blocking functional sites of the polypeptides with helper molecules, c) conjugating one or more non-polypeptide moieties to the blocked polypeptides, and d) identifying polypeptides with altered immunogenicity or increased stability.

25 Another method for altering, i.e., reducing or increasing, immunogenicity and/or increasing stability, e.g. functional *in vivo* half-life of a polypeptide of interest while maintaining a measurable function of the polypeptide involves the basic technical steps of the present invention, i.e.

- a) expressing a diversified population of nucleotide sequences encoding a polypeptide of  
30 interest,
- b) screening the polypeptides expressed in step a) for function, immunogenicity and/or stability,
- c) selecting functional polypeptides having altered immunogenicity and/or increased stability, e.g. functional *in vivo* half-life as compared to the polypeptide of interest, and

d) optionally subjecting the nucleotide sequence encoding the polypeptide selected in step to one or more repeated cycles of steps a)-c).

Yet another method for altering, i.e. reducing or increasing, immunogenicity and/or stability, e.g. functional *in vivo* half-life, of a polypeptide of interest while

- 5 maintaining a measurable function of the polypeptide, involves
- a) expressing a diversified population of nucleotide sequences encoding a polypeptide of interest,
  - b) conjugating one or more non-polypeptide moieties to the polypeptides expressed in step a),
  - 10 c) screening the resulting polypeptide conjugates for function, immunogenicity and/or stability,
  - d) selecting functional polypeptide conjugates having altered immunogenicity and/or increased stability, e.g. functional *in vivo* half-life, as compared to the polypeptide of interest, and
  - 15 e) optionally subjecting the nucleotide sequence encoding the polypeptide part of a polypeptide conjugate selected in step d) to one or more repeated cycles of steps a)-d).

A still further method of constructing a functional polypeptide conjugate having altered immunogenicity and/or increased stability, e.g. functional *in vivo* half-life, relative to a polypeptide of interest comprises

- 20 a) expressing a diversified population of nucleotide sequences encoding the polypeptide of interest,
- b) optionally conjugating one or more non-polypeptide moieties to the polypeptides expressed in step a),
  - c) screening the polypeptides expressed in step a) or, if made the polypeptide conjugates
  - 25 prepared in step b) for function, immunogenicity and/or stability,
  - d) selecting functional polypeptides or, if made, polypeptide conjugates having altered immunogenicity and/or increased stability, e.g. functional *in vivo* half-life, as compared to the polypeptide of interest, and
  - e) optionally subjecting the nucleotide sequence encoding the polypeptide or, if relevant,
  - 30 the polypeptide part of a polypeptide conjugate selected in d) to one or more repeated cycles of steps a)-d).

In still further aspects, the invention relates to a method for constructing a polypeptide conjugate with altered immunogenicity and/or increased stability, e.g. functional *in vivo* half-life, relative to a polypeptide of interest, which method comprises

- a) conjugating one or more non-polypeptide moieties to a polypeptide molecule expressed from a diversified population of nucleotide sequences encoding the polypeptide of interest,
- b) screening the resulting polypeptide conjugates for function, immunogenicity and/or stability,
- c) selecting functional polypeptide conjugates having having altered immunogenicity and/or stability, e.g. increased functional *in vivo* half-life, relative to the polypeptide of interest, and
- d) optionally subjecting the nucleotide sequence encoding the polypeptide part of a polypeptide conjugate selected in c) to one or more repeated cycles of steps a)-c).

In some embodiments, diversification is achieved by one or more of DNA shuffling, random mutagenesis, focused mutagenesis, and localized mutagenesis, as described in the section below entitled "Methods for creating a diversified population of nucleotide sequences". In some cases, the diversification process involves doping or spiking with oligonucleotides, e.g. as described in said same section. Optionally, the diversification process is performed recursively. If desired, one or more such diversified nucleotide sequence is further modified by site specific mutagenesis, e.g. in order to introduce or remove attachment groups for the non-polypeptide moiety of choice and thereby optimise the overall conjugation pattern of the polypeptide conjugate. Any of the methods of the invention may be conducted in microtiter plates or other available high throughput format, and offer an efficient, and thus attractive, solution for constructing functional polypeptides with altered immunogenicity and/or increased stability properties. In still further aspects, the invention relates to methods for preparing a polypeptide conjugate identified on the basis of any of the above-described methods.

25

## DETAILED DISCLOSURE OF THE INVENTION

The present invention offers an attractive solution to the problem of altering immunogenicity and/or increasing stability, e.g. functional *in vivo* half-life of polypeptides of interest. The solution provided by the present invention involves creating and selecting polypeptides with such improved properties, conveniently by use of a high throughput system. The possibility of creating and screening a large number of different polypeptides in a short time makes it possible to search several orders of magnitude more polypeptides than was possible by previously known approaches. Accordingly, the

invention enhances the chance of finding the optimal variant from the thousands or ten thousands of variants that may be produced.

The present invention is broadly applicable for the modification of the primary structure of a wide range of polypeptides. Furthermore, the methods apply to conjugation  
5 of modified polypeptides with a wide range of non-polypeptide moieties, in particular non-polypeptide moieties that are useful for altering, i.e. decreasing or increasing, immunogenicity and/or increasing stability, e.g. functional *in vivo* half-life, while maintaining function of the polypeptide of interest. In the present application, emphasis is placed on conjugation to non-polypeptide moieties such as polymers, lipophilic  
10 compounds, sugar moieties and organic derivatizing agents. However, it will be understood that the invention can be applied to other types of polypeptide conjugates as well – the only limitation being that the polypeptide can be conjugated to the non-polypeptide moiety of choice (either directly or through a suitable linker) and that the resulting polypeptide conjugate, in addition to the improved properties, is functional. It is  
15 intended that methods of preparing such other conjugates are included in the scope of protection afforded by the claims. Similarly, emphasis has been placed on constructing polypeptide conjugates with altered immunogenicity and/or increased functional *in vivo* half-life. However, it will be understood that the methods of the invention will be useful for constructing polypeptides with other improved properties, the only limitation being  
20 that the property to be improved is measurable. Thus, the present claims are also intended to cover the improvement of polypeptides with respect to such other properties.

Modification of polypeptides in accordance with a method of the present invention offers a number of advantages. In addition, or as an alternative, to the improved properties mentioned above (i.e., altered immunogenicity and/or increased functional *in vivo* half-life) in some instances, in particular when using the methods of the invention  
25 involving conjugation to a polymer, a sugar moiety and/or a lipophilic compound, one or more of the following properties can result: cell penetration capability is enhanced, the conjugate is protected from proteolytic digestion and subsequent abolition of activity; affinity for endogenous transport systems is improved, chemical stability against stomach  
30 acidity is improved, the function of the polypeptide is improved, e.g., the affinity towards specific surfaces is improved.

### Definitions

In the context of the present application and invention the following definitions apply:



The term “polypeptide conjugate” or “conjugate” is intended to indicate a chimeric (i.e. heterogeneous (in the sense of composite)) molecule formed by the covalent attachment of one or more polypeptide(s) to one or more non-polypeptide moieties such as polymer molecules, lipophilic compounds, sugar moieties or organic derivatizing agents. The term covalent attachment includes that the specified moieties are either directly covalently joined to one another, or else are indirectly covalently joined to one another through an intervening moiety or moieties, such as a bridge, spacer, or linkage moiety or moieties. Preferably, the chimeric molecule is soluble, such as water soluble, at relevant concentrations, i.e. soluble in physiological fluids such as blood. The term “non-conjugated polypeptide” is used about the polypeptide part of the conjugate. Preferred examples of a conjugate of the invention include a glycosylated polypeptide and a PEGylated polypeptide.

The term “non-polypeptide moiety” is intended to indicate a molecule, different from a peptide polymer composed of amino acid monomers and linked together by peptide bonds (except where the polymer is human albumin or another abundant plasma protein), which molecule is capable of conjugating to an attachment group of the polypeptide of the invention. The term “polymer molecule” is defined as a molecule formed by covalent linkage of two or more monomers. The term “polymer” may be used interchangeably with the term “polymer molecule”. Except where the number of polymer molecule(s) in the conjugate is expressly indicated every reference to “a polymer”, “a polymer molecule”, “the polymer” or “the polymer molecule” contained in a conjugate or otherwise used in a method of the present invention shall be a reference to one or more polymer molecule(s) in the conjugate.

The term “sugar moiety” is intended to indicate a carbohydrate-containing molecule comprising one or more monosaccharide residues, capable of being attached to the polypeptide (to produce a polypeptide conjugate in the form of a glycosylated polypeptide) by way of *in vivo* or *in vitro* glycosylation. The term “*in vivo* glycosylation” is intended to mean any attachment of a sugar moiety occurring *in vivo*, i.e. during posttranslational processing in a glycosylating cell used for expression of the polypeptide, e.g. by way of N-linked and O-linked glycosylation. Usually, the N-glycosylated sugar moiety has a common basic core structure composed of five monosaccharide residues, namely two N-acetylglucosamine residues and three mannose residues. The exact sugar structure depends, to a large extent, on the glycosylating organism in question and on the specific polypeptide. Depending on the host cell in question the glycosylation is classified

as a high mannose type, a complex type or a hybrid type. The term “*in vitro* glycosylation” is intended to refer to a synthetic glycosylation performed *in vitro*, normally involving covalently linking a sugar moiety to an attachment group of a polypeptide, optionally using a cross-linking agent. *In vivo* and *in vitro* glycosylation are  
5 discussed in detail further below. Alternative terms to sugar moiety include carbohydrate moiety, carbohydrate chain, oligosaccharide moiety or oligosaccharide chain.

The term “attachment group” is intended to indicate an amino acid residue group capable of coupling to a non-polypeptide moiety such as a polymer molecule, a lipophilic compound, a sugar moiety or an organic derivatizing agent suitable for use in the  
10 construction of a polypeptide conjugate by a method of the invention. For polymer conjugation, a frequently used attachment group is the  $\epsilon$ -amino group of lysine. Another attachment group is the N-terminal amino group of the polypeptide. Polymer molecules may also be coupled to free carboxylic acid groups, suitably activated carbonyl groups, oxidized carbohydrate moieties and mercapto groups. For instance, polymer attachment  
15 groups may be constituted by the carboxylic acid groups (-COOH) of amino acid residues in the polypeptide chain. Carboxylic acid polymer attachment groups may be the carboxylic acid group of aspartate or glutamate and the C-terminal COOH-group of the polypeptide. The sulfhydryl group of free Cys can be derivatized using, e.g., PEG-vinylsulphone. For conjugation to a lipophilic compound the following polypeptide  
20 groups may function as attachment groups: the N-terminal or C-terminal of the polypeptide, the hydroxy groups of the amino acid residues Ser, Thr or Tyr, the  $\epsilon$ -amino group of Lys, the SH group of Cys or the carboxyl group of Asp and Glu.

For *in vivo* N-glycosylation, the term “attachment group” is used in an unconventional way to indicate the amino acid residues constituting an N-glycosylation  
25 site (with the sequence N-X'-S/T/C-X'', wherein X' is any amino acid residue except proline, X'' any amino acid residue that may or may not be identical to X' and preferably is different from proline, N is asparagine and S/T/C is either serine, threonine or cysteine, preferably serine or threonine, and most preferably threonine). Although the asparagine residue of the N-glycosylation site is the one to which the sugar moiety is attached during  
30 glycosylation, such attachment cannot be achieved unless the other amino acid residues of the N-glycosylation site are present. Accordingly, when the non-polypeptide moiety is a sugar moiety and the conjugation is to be achieved by N-glycosylation, the term “amino acid residue comprising an attachment group for the non-polypeptide moiety” as used in connection with alterations of the amino acid sequence of the parent polypeptide is to be

understood as amino acid residues constituting an N-glycosylation site are to be altered in such a manner that either a functional N-glycosylation site is introduced into the amino acid sequence or removed from said sequence. An “O-glycosylation site” is the OH-group of a serine or threonine residue. For *in vitro* glycosylation useful attachment groups  
5 include those of arginine, histidine, a free carboxyl group, a free sulfhydryl group such as that of cysteine, a free hydroxyl group such as that of serine, threonine, or hydroxyproline, an aromatic residue such as that of phenylalanine, tyrosine or tryptophan or the amide group of glutamine. For coupling to an organic derivatizing agent an attachment group is typically N- or C-terminal residues, cysteine, histidine, lysine,  
10 arginine, aspartic acid or glutamic acid.

In the present application, amino acid names and atom names (e.g. CA, CB, NZ, N, O, C, etc) are used as defined by the Protein DataBank (PDB) ([www.pdb.org](http://www.pdb.org)) which are based on the IUPAC nomenclature (IUPAC Nomenclature and Symbolism for Amino Acids and Peptides (residue names, atom names e.t.c.), *Eur. J. Biochem.*, 138, 9-37  
15 (1984) together with their corrections in *Eur. J. Biochem.*, 152, 1 (1985). CA is sometimes referred to as C $\alpha$ , CB as C $\beta$ . The term “amino acid residue” is intended to indicate an amino acid residue contained in the group consisting of alanine (Ala or A), cysteine (Cys or C), aspartic acid (Asp or D), glutamic acid (Glu or E), phenylalanine (Phe or F), glycine (Gly or G), histidine (His or H), isoleucine (Ile or I), lysine (Lys or K),  
20 leucine (Leu or L), methionine (Met or M), asparagine (Asn or N), proline (Pro or P), glutamine (Gln or Q), arginine (Arg or R), serine (Ser or S), threonine (Thr or T), valine (Val or V), tryptophan (Trp or W), and tyrosine (Tyr or Y) residues. The terminology used for identifying amino acid positions/mutations is typically A15 (indicates an alanine residue in position 15 of the polypeptide), A15T (indicates replacement of the alanine  
25 residue in position 15 with a threonine residue), A15T,S (indicates replacement of the alanine residue in position 15 with a threonine residue or a serine residue). Multiple substitutions are indicated with a “+”, e.g. A15T+F57S means an amino acid sequence which comprises a substitution of the alanine residue in position 15 for a threonine residue and a substitution of the phenylalanine residue in position 57 for a serine residue.

30 The term “diversified population of nucleotide sequences encoding a polypeptide of interest” is intended to indicate ten or more nucleotide sequences, preferably at least 500, such as at least 1000 nucleotide sequences, which differ from each other in one or more nucleotides (thereby providing diversity), which population is capable of expressing a polypeptide which has one or more of the same functions as the polypeptide of interest

(such as a biological function), and, in addition, one or more modified properties (such as a different conjugation behavior, e.g., a different glycosylation pattern or differences in attachment group for a polymer or a lipophilic compound). In this context the term “same function” should be understood qualitatively, and not necessarily quantitatively. Since a  
5 critical element of the methods of the invention is the diversity of the population of nucleotide sequences, it will be understood that the exact identity of each of the nucleotide sequences constituting the diversified population is not important as long as the population contains nucleotide sequences encoding a polypeptide with relevant function(s) (which will be evident when conducting the screening and selection steps of a  
10 method of the invention). Accordingly, the term “encoding a polypeptide of interest” as used in the context of the diversified population of nucleotide sequences is intended to indicate that some, but normally far from all of the nucleotide sequences of the diversified population encode a polypeptide exhibiting one or more of the same functions as the polypeptide of interest. The polypeptides encoded by the diversified population and  
15 exhibiting one or more of the same functions as the polypeptide of interest is, e.g., identical to the polypeptide of interest or a variant thereof, i.e., differing in one or more amino acid residues as compared to the polypeptide of interest.

Typically, the diversified population is provided in the form of a nucleotide sequence library comprising nucleotide sequences which are created by random  
20 mutagenesis of a nucleotide sequence encoding the polypeptide of interest, or is the result of shuffling, e.g., between two or more homologous nucleotide sequences which are homologous to a nucleotide sequence encoding the polypeptide of interest and which themselves are sometimes created by random or site-directed mutagenesis of a nucleotide sequence encoding the polypeptide of interest. Normally, a main part, such as at least  
25 20%, typically at least 30% or at least 40%, more typically at least 50% or at least 60%, even more typically at least 70% or at least 80% of the nucleotide sequences display a nucleotide sequence identity of at least 40% identity, such as at least 50% or 60% identity, in particular at least 70% identity to each other.

The term “random mutagenesis” refers to a mutagenic process that is random with  
30 respect to the site of mutation within the subject nucleic acid, and that is random with respect to the mutations introduced, e.g., chemical mutagenesis, uv or  $\gamma$  irradiation, passage through repair deficient cells, etc. The term “localized mutagenesis” is used to indicate that the mutagenic process occurs preferentially in a predetermined portion or subsequence of the subject nucleic acid. “Focused mutagenesis” refers to a mutagenic

process that is biased with respect to the mutations produced, e.g., by codon preference, or oligonucleotide doping or spiking. In the context of the present invention, “site directed mutagenesis” refers to an alteration at a predetermined nucleotide position or positions, normally with the aim of altering one or more amino acid residues of the encoded amino acid sequence. The site-directed mutagenesis is normally designed on the basis of an analysis of a primary or tertiary (e.g. model) structure of the polypeptide to be modified.

The term “nucleotide sequence” is intended to indicate a consecutive stretch of two or more nucleotides molecules. The nucleotide sequence can be of genomic, cDNA, RNA, semisynthetic, synthetic origin, or any combinations thereof.

The “homology” or “identity” as used in connection with nucleotide or amino acid sequences is used in its conventional meaning. Amino acid sequence homology/identity is conveniently determined from aligned sequences (aligned by use of the CLUSTALW, version 1.74 using default parameters or provided from the PFAM families database version 4.0 (see Materials and Methods) by use of GENEDOC version 2.5 (Nicholas, K.B., Nicholas H.B. Jr., and Deerfield, D.W. II. 1997 GeneDoc: Analysis and Visualization of Genetic Variation, EMBNEW.NEWS 4:14; Nicholas, K.B. and Nicholas H.B. Jr. 1997 GeneDoc: Analysis and Visualization of Genetic Variation). Nucleotide sequence homology/identity is determined using the AlignX programme of the Vector NTI package available from Informax Inc.

The term “polymerase chain reaction” or “PCR” generally refers to a method for amplification of a desired nucleotide sequence *in vitro*, as described, for example, in US 4,683,195. In general, the PCR method involves repeated cycles of primer extension synthesis, using oligonucleotide primers capable of hybridising preferentially to a template nucleic acid.

“Cell”, “host cell”, “cell line” and “cell culture” are used interchangeably herein and all such terms should be understood to include progeny resulting from growth or culturing of a cell. “Transformation” and “transfection” are used interchangeably to refer to the process of introducing DNA into a cell. “Vector” refers to a plasmid or other nucleotide sequences that are capable of replicating within a host cell or being integrated into the host cell genome, and as such, are useful for performing different functions in conjunction with compatible host cells (a vector-host system): to facilitate the cloning of the nucleotide sequence of interest, i.e. to produce usable quantities of the sequence, to direct the expression of the gene product encoded by the sequence and to integrate the

nucleotide sequence of interest into the genome of the host cell. The vector will contain different components depending upon the function it is to perform.

“Operably linked” refers to the covalent joining of two or more nucleotide sequences, by means of enzymatic ligation or otherwise, in a configuration relative to one  
5 another such that the normal function of the sequences can be performed. For example, the nucleotide sequence encoding a presequence or secretory leader is operably linked to a nucleotide sequence for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide: a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; a ribosome binding site is operably  
10 linked to a coding sequence if it is positioned so as to facilitate translation. Generally, “operably linked” means that the nucleotide sequences being linked are contiguous and, in the case of a secretory leader, contiguous and in reading phase. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, then synthetic oligonucleotide adaptors or linkers are used, in conjunction with standard  
15 recombinant DNA methods.

The term “introduce” is intended to include substitution of an existing amino acid residue and insertion of additional amino acid residue. The term “remove” is intended to include substitution of the amino acid residue to be removed with another amino acid residue and deletion (without substitution) of the amino acid residue to be removed.

20 The term “immunogenicity” as used in connection with a given substance is intended to indicate the ability of the substance to induce a response from the immune system. Immune responses include both cell and antibody mediated responses. A substance which is capable of giving rise to an immune response may be called an immunogen (i.e., a substance which, when introduced into the circulatory system of a  
25 human or animal is capable of directly or indirectly stimulating an immunological response resulting in the formation of immunoglobulins or specific T-cells), an antigen (i.e., a substance which by itself is capable of generating antibodies when recognized as a non-self molecule and which is recognized by an antibody or T-cell receptor), or an allergen (i.e., an antigen which may give rise to allergic sensitization or an allergic  
30 response, e.g., by IgE antibodies in humans). See, e.g., Roitt: Essential Immunology (8<sup>th</sup> Edition, Blackwell) for further definition of immunogenicity.

The term “altered immunogenicity” is intended to indicate that the polypeptide conjugate produced by a method of the present invention gives rise to a measurably lower

altered, either reduced or increased, immune response than the polypeptide of interest as determined under comparable conditions.

The term “functional *in vivo* half-life” is used in its normal meaning, i.e. the time in which 50% of a given function (such as biological or catalytic activity) of the conjugate is retained, when tested *in vivo*, or in which half of the polypeptide conjugate molecules circulate in the plasma or bloodstream prior to being cleared, normally by the action of one or more of the reticuloendothelial systems (RES), kidney, spleen or liver, or by specific or unspecific proteolysis. Clearance depends on size (e.g. molecular weight or hydrodynamic volume) relative to the cutoff for glomerular filtration, shape/rigidity, charge, attached sugar chains, and the presence of cellular receptors for the protein. Alternative terms to “functional *in vivo* half-life” are “plasma clearance”, “serum half-life”, and “*in vivo* half-life”. It will be understood that functional *in vivo* half-life is of particular interest for pharmaceutical or veterinary polypeptides.

The term “increased functional *in vivo* half-life” is used to indicate that the functional *in vivo* half-life of the polypeptide conjugate is statistically significantly increased relative to that of the unconjugated polypeptide of interest as determined under comparable conditions. For instance, the functional *in vivo* half-life is increased at least 2 times, such as at least 10 times or at least 100 times as compared to that of the unconjugated polypeptide.

The term “function” is intended to indicate one or more specific functions of the polypeptide of interest. Typically, a given polypeptide has many different functions, examples of which are given further below in the section entitled “Screening for function”. Since methods of the present invention are generally applicable to polypeptides it will be understood that the meaning of the term has to be related to the polypeptide of interest. The term “function” is to be understood qualitatively (i.e., having a similar function as the polypeptide of interest) and not necessarily quantitatively (i.e., the magnitude of the function is not necessarily similar).

The term “stability” is used with respect to the polypeptide’s capability of resisting degradation or elimination when present in a relevant environment, e.g. under conditions of storage or use *in vitro* or *in vivo*. Examples of properties of relevance for stability include stability towards proteolytic degradation, pH, temperature, certain chemicals, resistance to glomerular filtration, etc. An “improved” or “increased” stability can, e.g. be measured in terms of functional *in vivo* half-life, plasma half life, shelf life (in

particular for industrial enzymes), etc., the specific parameter to be chosen usually depending on the environment in which the polypeptide is to be used.

The term “measurable function” or “functional polypeptide” is intended to indicate that the modified polypeptide resulting from the method of the invention has

5 preserved a sufficiently high function of interest to make it possible to measure the function by standard methods known in the art. In this context, the term “measurable” should be considered in relation to the specific use of the polypeptide of interest. For instance, if the polypeptide is a hormone and the function of interest is the hormone’s affinity towards a specific receptor a measurable function is defined to be an observable

10 affinity between the hormone and the receptor as determined by the normal methods used for measuring such affinity. If the polypeptide is an enzyme and a function of interest is the enzyme activity a measurable function is the enzyme’s ability to catalyze a reaction involving the normal substrates of the enzyme as measured by the normal methods for determining the enzyme activity in question. It will be understood that the magnitude of a

15 “measurable function” is related to the polypeptide of interest and thus may vary considerably among different polypeptides. Normally, a measurable function is at least 1%, such as at least 5% of the function of the unmodified or non-conjugated polypeptide of interest, such as at least 10% as measured under comparable conditions. Preferably, a measurable function is 15%, such as at least 25%, in particular at least 40% and more

20 preferably at least 50% of the function of the unmodified or non-conjugated polypeptide of interest as measured under comparable conditions. Most preferably, a measurable function is at least 60%, such as at least 75%, in particular at least 80% or at least 95% of the function of the unmodified or non-conjugated polypeptide of interest. In certain cases the measurable function is at least 100% such as at least 120% of the unmodified or

25 non-conjugated polypeptide of interest as determined under comparable conditions. In the present context the term “functional site” is intended to indicate one or more amino acid residues which is/are essential for or otherwise involved in the function or performance of the polypeptide, i.e., the amino acid residues which mediates a desired biological activity of the polypeptide in question. Such amino acid residues are “located

30 at” the functional site. The functional site can be determined by methods known in the art and is preferably identified by analysis of a structure of the polypeptide complexed to a relevant ligand. For instance, the functional site can be a binding site, a catalytic site, a regulatory site, or an interaction site. The polypeptide of interest can have one or more functional sites. For instance, when the polypeptide is an enzyme a functional site



comprises the amino acid residues making up the catalytic site, e.g., the catalytic triad of serine proteases, and/or amino acid residues involved in substrate binding. When the polypeptide is a hormone or a growth factor a functional site is normally a binding site such as a receptor-binding site. Typically, the growth factor or hormone has several  
5 binding sites. When the polypeptide is an antibody a functional site is, e.g., an antigen-binding site. Normally, an antibody has two antigen-binding sites. When the polypeptide is a regulatory protein, a typical functional site is an interaction site. When the polypeptide is a receptor a typical functional site is a ligand binding site or a signalling/effector site. When the polypeptide is an enzyme inhibitor a functional site is a  
10 site interacting with the functional site of the enzyme.

The term “equivalent position” is intended to indicate a position in the amino acid sequence of a given polypeptide, which is homologous (i.e., corresponding in position in either primary or tertiary structure) to a position in the amino acid sequence of another polypeptide belonging to the same polypeptide sequence family. Where possible, the  
15 “equivalent position” is conveniently determined on the basis of an alignment of members of the polypeptide sequence family in question, suitably prepared by using the alignment program CLUSTALW version 1.74, or from the PFAM protein families database (*see*, Materials and Methods).

The term “polypeptide sequence family” is used in its conventional meaning, i.e.,  
20 to indicate a group of polypeptides, which are related to each other by function and structure in terms of having an amino acid sequence which exhibits a sufficient degree of homology to allow alignment of the sequences. An alternatively used term is “protein sequence family”. Polypeptide sequence families are available, e.g. from the PFAM families, version 4.0, or can be prepared by use of a suitable computer program such as  
25 CLUSTALW version 1.74. The preparation of a polypeptide sequence family is described in further detail in the Materials and Methods section hereinafter.

The term “high throughput screening” is intended to indicate a screening of a large number of samples (such as more than 100 samples per day). The screening can be conducted manually, but is preferably done using an automatized or semi-automatized  
30 system.

#### *Polypeptide of interest*

In the present context the term “polypeptide of interest” is intended to indicate any molecule that comprises a stretch of two or more amino acid residues, typically at least 20

amino acid residues. In addition, the polypeptide of interest can be post-translationally modified and thereby comprise other types of molecules such as sugar moieties (apart from any sugar moieties to which the polypeptide of interest can be conjugated by a method of the present invention). Preferably, the polypeptide of interest is a protein, a  
5 glycoprotein or an oligopeptide that contains in the range of 30 to 4500 amino acids, preferably in the range of 40 to 3000 amino acids.

The methods of the present invention are broadly applicable. The polypeptide can be of any origin, including microbial, mammalian, plant and insect origin as long as it is encoded by a nucleotide sequence, which is capable of being modified according to a  
10 method of the present invention. For instance, the microbial polypeptide is of fungal, yeast or bacterial origin; the mammalian polypeptide is of human, porcine, ovine, urcine, murine, rabbit, donkey, or bat origin. Furthermore, the polypeptide can be of snake, leech, frog or mosquito origin. Preferably, the polypeptide of interest is of microbial origin or of human origin.

15 It will be understood that the term "polypeptide of interest" includes at least the following types of polypeptides:

Native or wild type polypeptides, i.e., polypeptides that can be found in nature; polypeptides which have been prepared by genetic or other modification of a native or wildtype polypeptide (e.g., by substitution, deletion or truncation of one or more amino  
20 acid residues of the polypeptide or by addition or insertion of one or more amino acid residues into the polypeptide) so as to modify the amino acid sequence constituting said native or wildtype polypeptide, e.g., by modification of a polynucleotide encoding the polypeptide of interest. This polypeptide type is also termed "a variant"; polypeptides, which for other reasons are different from those found in nature.

25 The polypeptide of interest can be a pharmaceutical or veterinary polypeptide, i.e., a polypeptide that is physiologically active when introduced into the circulatory system of or otherwise administered to a human or an animal, or a diagnostic polypeptide intended for use in diagnosis. Furthermore, the polypeptide of interest can be an industrial polypeptide intended for industrial uses such as e.g., in the manufacture of goods wherein  
30 the polypeptide constitutes a functional ingredient or wherein the polypeptide is used for processing or other modification of raw ingredients during the manufacturing process. The industrial polypeptide is typically an enzyme and can be used in products or in the manufacture of products such as detergents, household articles, personal care products, agrochemicals, textile, food products, in particular bakery products, feed products, or in

industrial processes such as hard surface cleaning. The industrial polypeptide is normally not intended for internal administration to humans or animals.

For example, the polypeptide of interest is an antibody or antibody fragment, immunoglobulin or immunoglobulin fragment, a plasma protein, an erythrocyte or thrombocyte protein, a cytokine, a growth factor, a binding protein, a profibrinolytic protein, a protease inhibitor, an antigen, an enzyme, a ligand, a receptor, or a hormone. In the present context, the term “antibody” includes single monoclonal antibodies (including agonist and antagonist antibodies) and antibody compositions with polyepitopic specificity that can also be termed polyclonal antibodies. The term “monoclonal antibody” is used in its conventional meaning to indicate a population of antibodies of substantially homogeneous antibodies. The individual antibodies comprised in the population have identical binding affinities and vary structurally only to a limited extent. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to conventional (polyclonal) antibody preparations that typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. Preferred antibody targets for the present invention are human or humanized monoclonal antibodies.

“Antibody fragment” is defined as a portion of an intact antibody comprising the antigen binding site or the entire or part of the variable region of the intact antibody, wherein the portion is free of the constant heavy chain domains (i.e. CH<sub>2</sub>, CH<sub>3</sub>, and CH<sub>4</sub>, depending on antibody isotype) of the Fc regions of the intact antibody. Examples of antibody fragments include Fab, Fab', Fab'-SH, F(ab')<sub>2</sub>, and Fv fragments; diabodies; any antibody fragment that is a polypeptide having a primary structure consisting of one uninterrupted sequence of contiguous amino acid residues (which can also be termed a single chain antibody fragment or a single chain polypeptide).

Immunoglobulins of interest include IgG, IgE, IgM, IgA, IgD and fragments thereof. More specifically, the polypeptide of interest can be i) a plasma protein, e.g. a factor from the coagulation system, such as Factor VII, Factor VIII, Factor IX, Factor X, Factor XIII, thrombin, protein C, antithrombin III or heparin co-factor II, a factor from the fibrinolytic system such as pro-urokinase, urokinase, tissue plasminogen activator, plasminogen activator inhibitor 1 (PAI-1) or plasminogen activator inhibitor 2 (PAI-2), the Von Willebrand factor, or an  $\alpha$ -1-proteinase inhibitor, ii) a erythrocyte or thrombocyte protein, e.g. hemoglobin, thrombospondin or platelet factor 4, iii) a cytokine, e.g. an interleukin

such as interleukin (IL) 1, IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, IL-16, IL-17, IL-18, or IL-1Ra, an interferon such as interferon- $\alpha$ , interferon- $\beta$  or interferon- $\gamma$ , a colony-stimulating factor such as GM-CSF or G-CSF, stem cell factor (SCF), a member of the tumor necrosis factor family (e.g. TNF- $\alpha$ , lymphotoxin- $\alpha$ , lymphotoxin- $\beta$ , FasL, CD40L, CD30L, CD27L, Ox40L, 4-1BBL, RANKL, TRAIL, 5 TWEAK, LIGHT, TRANCE, APRIL, THANK or TALL-1), iv) a growth factor, e.g. platelet-derived growth factor (PDGF), transforming growth factor  $\alpha$  (TGF- $\alpha$ ), transforming growth factor  $\beta$  (TGF- $\beta$ ), epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), somatotropin (growth hormone), a somatomedin such as insulin-like growth factor I (IGF-I) or insulin-like growth factor II (IGF-II), 10 erythropoietin (EPO), thrombopoietin (TPO) or angiopoietin, v) a profibrinolytic protein, e.g. staphylokinase or streptokinase, vi) a protease inhibitor, e.g. aprotinin or CI-2A, vii) an enzyme, e.g. superoxide dismutase, catalase, uricase, bilirubin oxidase, trypsin, papain, asparaginase, arginase, arginine deiminase, adenosin deaminase, ribonuclease, alkaline 15 phosphatase,  $\beta$ -glucuronidase, purine nucleoside phosphorylase or batroxobin, viii) an opioid, e.g. endorphins, enkephalins or non-natural opioids, ix) a hormone or neuropeptide, e.g. insulin, calcitonin, glucagons, adrenocorticotrophic hormone (ACTH), somatostatin, gastrins, cholecystokinins, parathyroid hormone, luteinizing hormone, gonadotropin-releasing hormone, chorionic gonadotropin, corticotropin-releasing factor, 20 vasopressin, oxytocin, antidiuretic hormones, thyroid-stimulating hormone, thyrotropin-releasing hormone, relaxin, glucagon-like peptide 1 (GLP-1), glucagon-like peptide 2 (GLP-2), prolactin, neuropeptide Y, peptide YY, pancreatic polypeptide, leptin, orexin, CART (cocaine and amphetamine regulated transcript), a CART-related peptide, melanocortins (melanocyte-stimulating hormones), melanin-concentrating hormone, 25 follicle-stimulating hormone, natriuretic peptides, adrenomedullin, endothelin, exendin, secretin, amylin (IAPP; islet amyloid polypeptide precursor), vasoactive intestinal peptide (VIP), pituitary adenylate cyclase activating polypeptide (PACAP), agouti and agouti-related peptides or somatotropin-releasing hormones, or x) another type of protein or peptide such as thymosin, bombesin, bombesin-like peptides, heparin-binding protein, 30 soluble CD4, pigmentary hormones, hypothalamic releasing factor, melanotons or phospholipase activating protein.

Examples of, in particular industrial, enzymes include hydrolases, such as proteases or lipases, oxidoreductases, such as laccase and peroxidase, transferases such as transglutaminases, isomerases, such as protein disulphide isomerase and glucose

isomerase, cell wall degrading enzymes such as cellulases, xylanases, pectinases, mannanases, etc., amylolytic enzymes such as endoamylases, e.g., alpha-amylases, or exo-amylases, e.g., beta-amylases or amyloglucosidases, etc.

#### 5 *Methods for creating a diversified population of nucleotide sequences*

The diversified population of nucleotide sequences encoding a polypeptide of interest is prepared by any suitable method known in the art. For example, the diversified population can be prepared by methods involving gene shuffling, other recombination between nucleotide sequences, random, localized or focused mutagenesis or any

10 combination of these methods.

For example, the diversified population of nucleotide sequences can be prepared from two or more nucleotide sequences which are sufficiently homologous to allow recombination between the sequences or parts thereof. For instance, the diversified population of nucleotide sequences is prepared by combination between such sequences

15 or parts thereof. The combination of nucleotide sequences or sequence parts is conveniently conducted by methods known in the art, for instance methods which involve homologous cross-over such as disclosed in US 5,093,257, or methods which involve gene shuffling, i.e., recombination between two or more homologous nucleotide sequences resulting in new nucleotide sequences having a number of nucleotide  
20 alterations when compared to the nucleotide sequences used for the recombination. In order for homology based nucleic acid shuffling to take place the nucleotide sequences is preferably at least 50% identical, such as at least 60% identical, more preferably at least 70% identical, such as at least 80% identical. The recombination can be performed *in vitro* or *in vivo*. Examples of suitable *in vitro* gene shuffling methods are disclosed by  
25 Stemmer et al (1994), Proc. Natl. Acad. Sci. USA; vol. 91, pp. 10747-10751; Stemmer (1994), Nature, vol. 370, pp. 389-391; Smith (1994), Nature vol. 370, pp. 324-325; Zhao et al., Nat. Biotechnol. 1998, Mar; 16(3): 258-61; Zhao H. and Arnold, FB, Nucleic Acids Research, 1997, Vol. 25. No. 6 pp. 1307-1308; Shao et al., Nucleic Acids Research 1998, Jan 15; 26(2): pp. 681-83; and WO 95/17413. Example of a suitable *in vivo* shuffling  
30 method is disclosed in WO 97/07205.

Furthermore, the diversified population of nucleotide sequences can be a randomly mutagenized library, conveniently prepared by subjecting a nucleotide sequence encoding the polypeptide of interest to mutagenesis to create a large number of mutated nucleotide sequences. The mutagenesis can be entirely random,

both with respect to where in the nucleotide sequence the mutagenesis occurs and with respect to the nature of mutagenesis. Alternatively, the mutagenesis can be conducted so as to randomly mutate one or more selected regions of the polypeptide ("localized mutagenesis"), and/or directed towards introducing certain types of amino acid residues, in particular amino acid residues containing an attachment group, at random into the polypeptide molecule or at random into one or more selected regions of the polypeptide ("focused mutagenesis"). Besides substitutions, the mutagenesis can also cover random introduction of insertions or deletions. Preferably, the insertions are made in reading frame, e.g., by performing multiple introduction of three nucleotides as described by Hallet et al., *Nucleic Acids Res.* 1997, 25(9):1866-7 and Sondek and Shrotle, *Proc Natl. Acad. Sci USA* 1992, 89(8):3581-5.

The random mutagenesis (either of the whole nucleotide sequence or of one or more selected regions of the nucleotide) can be performed by any suitable method. For example, the mutagenesis is performed using a suitable physical or chemical mutagenizing agent, a suitable oligonucleotide, PCR generated mutagenesis or any combination of these mutagenizing agents and/or other methods according to state of the art technology, e.g. as disclosed in WO 97/07202.

Error prone PCR generated mutagenesis, e.g. as described by J.O. Deshler (1992), *GATA* 9(4): 103-106 and Leung et al., *Technique* (1989) Vol. 1, No. 1, pp. 11-15, is particularly useful for mutagenesis of longer peptide stretches (corresponding to nucleotide sequences containing more than 100 bp) or entire genes, and are preferably performed under conditions that increase the misincorporation of nucleotides.

Mutagenesis based on doped or spiked oligonucleotides or by specific sequence oligonucleotides, is of particular use for mutagenesis of one or more regions containing shorter nucleotide sequences (normally containing less than 100 nucleotides per region). Mutagenesis of several regions is conveniently conducted by spiking with several oligos and combining them by PCR. Doping or spiking with oligonucleotides can also be used for random mutagenesis of nucleotide sequences encoding longer peptide stretches or entire genes when it is desirable to be able to control the random mutagenesis to a higher extent than is possible with error prone PCR generated mutagenesis.

In some embodiments, localized or focused mutagenesis of one or more selected regions of a nucleotide sequence encoding the polypeptide of interest is performed using PCR generated mutagenesis, in which one or more suitable oligonucleotide primers flanking the area to be mutagenized are used. In some cases, doping or spiking with

oligonucleotides is used to introduce mutations so as to remove or introduce attachment groups for a non-polypeptide moiety of interest. Preferably, the spiking or doping is designed to avoid the introduction of codons for unwanted amino acid residues (by lowering the amount of or completely avoiding the nucleotides resulting in these codons) or to increase the likelihood that a particular type of amino acid residue (e.g. an amino acid comprising an attachment group for the non-polypeptide moiety of interest) is introduced into a desired position or region of the polypeptide (by increasing the number of codons for the amino acid residue). State of the art knowledge and computer programs (e.g. as described by Siderovski DP and Mak TW, *Comput. Biol. Med.* (1993) Vol. 23, No. 6, pp. 463-474 and Jensen et al. *Nucleic Acids Research*, 1998, Vol. 26, No. 3) can be used for calculating the most optimal nucleotide mixture for a given amino acid preference. The oligonucleotides can be incorporated into the nucleotide sequence encoding the polypeptide of interest by any published technique using e.g. PCR, LCR or any DNA polymerase or ligase.

In a preferred embodiment, the mutagenesis is localized to two, three, four, five, six or more regions at the same time by synthesizing random, doped, biased and/or specific oligonucleotides covering each region and assembling the oligonucleotides by state of the art technologies, for example by a PCR method. One convenient PCR method involves a PCR in which the nucleotide sequence encoding the polypeptide of interest is used as a template and, e.g., random, doped, biased and/or specific oligonucleotides are used as primers. In addition, cloning primers localized outside the targetted regions can be used. The resulting PCR product can either directly be cloned into an appropriate expression vector or gel purified and amplified in a second PCR reaction using the cloning primers and cloned into an appropriate expression vector.

In addition to the recombination, shuffling, random, localized and focused mutagenesis methods described herein, it is occasionally useful to employ site specific mutagenesis techniques to modify one or more selected amino acids in a polypeptide of interest in the context of the present diversification and screening methods. Site-specific mutagenesis can be conducted in any part of the polypeptide, e.g. within a region which has already been modified by a method of the invention or outside such region. Site-specific mutagenesis is conveniently designed on the basis of a primary or tertiary (e.g. model structure) of the modified polypeptide or polypeptide conjugate resulting from a method of the invention. The site-specific mutagenesis is normally followed by screening for function and one or more improved properties as described herein.

The nucleotide sequence(s) or nucleotide sequence region(s) to be mutagenized is typically present on a suitable vector such as a plasmid or a bacteriophage, which as such is incubated with or otherwise exposed to the mutagenizing agent. The nucleotide sequence(s) to be mutagenized can also be present in a host cell either by being integrated  
5 into the genome of said cell or by being present on a vector harboured in the cell. Alternatively, the nucleotide sequence to be mutagenized is in isolated form. The nucleotide sequence is preferably a DNA sequence such as a cDNA, genomic DNA or synthetic DNA sequence.

Subsequent to the incubation with or exposure to the mutagenizing agent, the  
10 mutated nucleotide sequence, normally in amplified form, is expressed by culturing a suitable host cell carrying the nucleotide sequence under conditions allowing expression to take place. The host cell used for this purpose is one, which has been transformed with the mutated nucleotide sequence(s), optionally present on a vector, or one which carried the nucleotide sequence during the mutagenesis, or any kind of gene library. A host cell  
15 of choice for screening is one capable of a reasonable transformation frequency such as bacterium, yeast or fungus. Alternatively, a high throughput transfection system of mammalian cells or other cells capable of a desirable post-translational modification can be employed. The latter is of particular interest when post-translational processing is of importance and examples include CHO (Chinese Hamster Ovary) and COS and BHK  
20 (Baby Hamster Kidney) cells.

*Strategies for preparing a diversified population of nucleotide sequences*

An analysis of which amino acid residue(s) or region(s) of the polypeptide of interest constitute(s) preferred target(s) for modification, e.g., by use of localized or focused  
25 mutagenesis techniques, is suitably performed as described in the Materials and Methods section herein. Alternatively, such modification is performed randomly as described in further detail hereinafter. The identity of the attachment group to be introduced/removed depends on the identity of the non-polypeptide moiety to which the polypeptide is to be conjugated, e.g. as evident from the "Definitions" section herein.

30 According to one embodiment of the invention the diversified population of nucleotide sequences is constructed by localizing the random mutagenesis (e.g. to introduce and/or remove amino acid residues comprising attachment group) to one or more defined region(s) of the polypeptide of interest, "localized mutagenesis." For instance, the mutagenesis is focused by being designed to introduce amino acid residues



with an attachment group for a polymer molecule, a lipophilic compound, a sugar moiety or an organic derivatizing agent in one or more specified regions and/or to remove such (or other) residues from one or more other regions of the polypeptide of interest. In the present context, the term “region” is intended to include a single amino acid residue as  
5 well as a group of two, three, four or more amino acid residues which are located closely together either in the three-dimensional structure or the primary structure of the polypeptide of interest.

According to one embodiment of the present invention, a region to be selected for localized or focused mutagenesis is a region that can advantageously be enriched in one  
10 or more amino acid residues, containing an attachment group for the non-polypeptide moiety in question. For instance, the region is selected from the following group of regions:

A region that contains one or more amino acid residues potentially exposed to the surface of the polypeptide of interest.

15 A region that contains one or more amino acid residues occupying an equivalent position to a residue in any of the other members of the protein sequence family, which comprises an attachment group (only including those family members having an amino acid sequence which has 40% or higher identity to the given protein amino acid sequence).

A region in which one or more amino acid residues containing an attachment group can  
20 be inserted by way of conservative mutation of one or more existing amino acid residues, e.g., to mutate Arg to Lys, Asn to Asp and/or Gln to Glu.

A region in which one or more amino acid residues having their CB (or CA in the case of Gly) at a distance of more than 8 Å, such as more than 10 Å from CB of the attachment group of the nearest amino acid residue containing such group (in order to obtain a  
25 balanced distribution of attachment groups at the surface of the polypeptide of interest).

A region wherein one or more amino acid residues having their CB (or CA in the case of Gly) at a distance of more than 10 Å from the attachment group of the nearest amino acid residue containing such group (in order to obtain a balanced distribution of attachment groups at the surface of the polypeptide of interest).

30 A region that comprises one or more amino acid residues present in a known epitope region (i.e. amino acid residues contributing to an epitope or located in such a manner that conjugation of a non-polypeptide moiety to the amino acid residue shields an epitope), the epitope region, e.g., being identified by epitope mapping.

In particular, it can be of interest to perform localized or focused mutagenesis of amino acid residues in more than one of the above-mentioned regions. For instance, localized or focused mutagenesis is conveniently performed in a region containing amino acid residue(s) potentially exposed at the surface of the polypeptide and that also belongs  
5 to one of the other above specified regions.

Furthermore, in accordance with this embodiment, mutagenesis is conducted in one, and preferably two or more part(s) of the nucleotide sequence corresponding to one or more of the above region(s) of the polypeptide of interest to introduce an amino acid residue containing an attachment group into this/these region(s). Preferably, the region(s)  
10 to be mutagenized does/do not contain an amino acid residue or contain(s) only few, e.g., one or two amino acid residues having an attachment group. Furthermore, in order to preserve function of the polypeptide of interest it is sometimes desirable that the amino acid residue(s) to be introduced, which contain(s) an attachment group, is/are not introduced at a functional site of the polypeptide of interest.

15 In order to ensure introduction of amino acid residue(s), e.g., containing an attachment group, focused mutagenesis is used, conveniently designed in such a way that the resulting diversified population of nucleotide sequences is enriched in codons encoding such amino acid residue(s). Preferably, the diversified population of nucleotide sequences is enriched in sequences encoding one or more amino acid residue(s) selected  
20 from the group consisting of lysine, arginine, aspartic acid, glutamic acid, tyrosine and cysteine. For example, when the non-polypeptide moiety is a polymer molecule, enrichment in lysine residues is particularly desirable. Preferably, the diversified population of nucleotide sequences is enriched in codons specifying one or more amino acid residue(s) selected from the group consisting of Lys, Ser, Thr, Tyr, Cys, Asp and  
25 Glu, when the non-polypeptide moiety is a lipophilic compound. Preferably, the diversified population of nucleotide sequences encode polypeptides enriched in one or more amino acid residue(s) selected from the group consisting of an N-glycosylation site, arginine, histidine, cysteine, serine, threonine, hydroxyproline, phenylalanine, tyrosine and tryptophan, when the non-polypeptide moiety is a sugar moiety. Preferably, the  
30 diversified population of nucleotide sequences encode polypeptides enriched in one or more amino acid residue(s) selected from the group consisting of lysine, arginine, aspartic acid, glutamic acid, histidine and cysteine, when the non-polypeptide moiety is an organic derivatizing agent.

Focused mutagenesis is conveniently carried out by doping or spiking the mutagenic reaction with oligonucleotides. The doping or spiking can be designed on the basis of the skilled person's intelligent consideration of nucleotide coding parameters (in accordance with generally known principles), by use of a suitable algorithm, e.g. a  
5 computer program which is based on the algorithm described by Jensen et al. 1998 or Sedrovski and Mak (1993) (see above), or by using trinucleotides (Sondek, J. and Shortle, D., *Proc. Natl. Acad. Sci. USA*, Vol. 89, pp. 3581-3585, April 1992; Kayushin et al., *Nucleic Acids Research*, 1996, Vol. 24, No. 19, pp. 3748-3755; Virnekäs et al., *Nucleic Acids Research*, 1994, Vol. 22, No. 25; WO 93/21203).

10 In the present context, the term "enriched" is intended to indicate that the nucleotide sequence resulting from the mutagenesis contains more codons encoding the amino acid residue(s) in question than the unmutated nucleotide sequence or subsequence thereof. The term "enriched" is also intended to include the situation where one or more codons encoding the amino acid residue(s) in question is/are introduced into a sequence  
15 which does not contain such codons prior to mutagenesis.

In some circumstances, it is disadvantageous to have two or more attachment groups for the non-polypeptide moiety of choice located in close proximity to each other, because a heterogeneous population of polypeptide conjugates (such as polypeptide-polymer conjugates) can result if it is possible only to conjugate one of the two or more  
20 attachment groups (because of steric hindrance for conjugation of more than one group) or if only a subpopulation of the polypeptide conjugates have two or more attachments sites conjugated. More than one attachment site in a region can also increase the likelihood that an unnecessary decrease in function will occur. One way to avoid the introduction of more than one amino acid residue containing an attachment group into a  
25 given region is to conduct focused mutagenesis of this region in such a manner that each of the oligonucleotides employed in the focused mutagenesis encodes only one amino acid residue constituting an attachment group. This generally applicable approach is further described in Example 2.

In one embodiment, the diversified population of nucleotide sequences is designed  
30 so as to reduce the number of codons encoding an amino acid residue containing an attachment group, e.g., to remove two, three or four such amino acid residues from the polypeptide of interest. In particular, it is desirable to remove such amino acid residue(s) located at a functional site of the polypeptide in order to preserve or reduce a loss of

function resulting from conjugation, e.g., glycosylation, PEGylation or other conjugation at such residue(s).

Also, if the polypeptide of interest contains two or more attachment groups located closely together (either in the primary or tertiary structure of the polypeptide), it  
5 can be advantageous to remove amino acid residues containing such groups in order to ensure that only one attachment group is available for conjugation within a given region of the polypeptide, thus, ensuring a more homogenous population of conjugated polypeptides. Accordingly, in a further embodiment, polypeptides having amino acid residues containing attachment groups that are separated by less than three residues in the  
10 primary sequence and/or having amino acids with attachment groups separated by less than 10 Å, preferably less than 8 Å, and more preferably less than 5 Å are targets for mutagenesis.

Preferably, the amino acid residues to be removed in the above embodiments are selected from the group consisting of lysine, arginine, aspartic acid, glutamic acid,  
15 tyrosine and cysteine, in particular lysine, when the non-polypeptide moiety is a polymer molecule; the group consisting of Lys, Ser, Thr, Tyr, Cys, Asp and Glu, when the non-polypeptide moiety is a lipophilic compound; the group consisting of an N-glycosylation site, arginine, histidine, cysteine, serine, threonine, hydroxyproline, phenylalanine, tyrosine and tryptophan, when the non-polypeptide moiety is a sugar moiety; and the  
20 group consisting of lysine, arginine, aspartic acid, glutamic acid, histidine and cysteine, when the non-polypeptide moiety is an organic derivatizing agent. The mutation should preferably be towards introduction of a residue which does not contain an attachment group, more preferably towards an amino acid residue present at the equivalent position in the protein sequence family in question and/or the towards a conservative amino acid  
25 substitution.

Examples of conservative substitutions are within the group of basic amino acids (such as arginine, lysine and histidine), acidic amino acids (such as glutamic acid and aspartic acid), polar amino acids (such as glutamine and asparagine), hydrophobic amino acids (such as leucine, isoleucine and valine), aromatic amino acids (such as  
30 phenylalanine, tryptophan and tyrosine), and small amino acids (such as glycine, alanine, serine, threonine and methionine). Amino acid substitutions that do not generally alter the specific activity are known in the art and are described, for example, by H. Neurath and R.L. Hill, 1979, *In, The Proteins*, Academic Press, New York. The most commonly occurring exchanges are Ala/Ser, Val/Ile, Asp/Glu, Thr/Ser, Ala/Gly, Ala/Thr, Ser/Asn,

Ala/Val, Ser/Gly, Tyr/Phe, Ala/Pro, Lys/Arg, Asp/Asn, Leu/Ile, Leu/Val, Ala/Glu, and Asp/Gly as well as these in reverse.

Furthermore, doping or spiking to introduce or remove attachment groups can be designed so as to ensure a balanced number of attachment groups relative to the  
5 molecular weight and/or surface area of the polypeptide. For instance, the heavier the polypeptide is the more non-polypeptide moieties, such as polymer molecules, should be coupled to the polypeptide to obtain sufficient shielding of epitope(s) responsible for antibody formation.

When the non-polypeptide moiety to which the polypeptide of interest is to be  
10 conjugated is a sugar moiety, and the conjugation is conducted by way of *in vivo* glycosylation, the attachment group(s) to be introduced is a potential N-glycosylation site or O-glycosylation site. Accordingly, for this purpose the mutagenesis is conducted towards introduction of such N- or O-glycosylation site(s) at a suitable position in the polypeptide of interest. An N-glycosylation site can be introduced anywhere in the  
15 sequence by up to three mutations where the Asn residue is potentially exposed to the surface of the polypeptide of interest and is not located at the N-terminal residue.

Preferably, localized or focused mutagenesis is performed to result in two or all of the residues being potentially exposed to the surface of the polypeptide of interest.

Conveniently, the mutagenesis is conducted towards introduction of one, two or all of the  
20 amino acid residues making up the N-glycosylation site at positions where the equivalent position in another member of the protein sequence family has one or both of the mutation type residues (Asn or Ser/Thr), more preferably at positions where one of the residues is already present in the amino acid sequence of the polypeptide of interest (i.e., the Asn or the Ser or the Thr are in positions allowing a mutation of a conservative  
25 type, which in this particular context is defined as Asp->Asn, Gln->Asn, Ala->Ser, Gly->Ser, Ala->Thr, Gly->Thr.

### Conjugation

In a desirable embodiment of the method of the invention wherein the screening and  
30 selection steps are performed directly on the expressed polypeptides a) without a prior conjugation step, it can be desirable – after screening and selection – to conjugate selected polypeptides to a non-polypeptide moiety, e.g. to a polymer molecule, a lipophilic compound, a sugar moiety (e.g., by way of *in vitro* glycosylation) and/or an organic

chemical derivative, in order to obtain a further decrease of immunogenicity and/or increase of functional *in vivo* half-life.

In other methods of the invention, conjugation to a non-polypeptide moiety is an integral step. It will be understood that such conjugation step only finds relevance when a non-polypeptide moiety other than an *in vivo* attached sugar moiety is to be conjugated to the polypeptide, since *in vivo* glycosylation takes place during the expression step when using an appropriate glycosylating host cell as expression host. Accordingly, whenever a conjugation step occurs in the present invention this is intended to be conjugation to a non-polypeptide moiety other than a sugar moiety attached by *in vivo* glycosylation.

10 The polypeptide conjugate prepared by a method of the invention can comprise a variety of different numbers of non-polypeptide moieties, e.g. 1-20 non-polypeptide moieties, such as 1-10 or 2-10 non-polypeptide moieties.

In accordance with the invention conjugation to two or more different types of non-polypeptide moieties can be performed. For instance, the polypeptide expressed from the diversified population of nucleotide sequences can be conjugated to a polymer molecule and a lipophilic compound, to a polymer and a sugar moiety (e.g. by *in vivo* glycosylation), to a lipophilic compound and a sugar moiety (e.g. by *in vivo* glycosylation), etc. in order to obtain a further decrease of immunogenicity and/or increase of functional *in vivo* half-life. The conjugation to two or more different non-polypeptide moieties can be done simultaneously or sequentially. In the following sections "Conjugation to a lipophilic compound", "Conjugation to a polymer molecule", "Conjugation to a sugar moiety" and "Conjugation to an organic derivatizing agent" conjugation to specific types of non-polypeptide moieties is described.

15 20

Generally, it is desirable to conjugate various moieties, as described herein, to functional polypeptides. However, the methods of the invention are equally applicable to the diversification and selection of subportions of polypeptides that are useful biologically or experimentally in the absence of one or all of their native functions. For example, numerous immunogenic epitopes useful for the production of antibodies, e.g., as vaccines, or therapeutic or experimental reagents, require sugar attachments. The methods described herein can be employed to engineer epitopes that are favorably glycosylated *in vivo* or *in vitro*, regardless of whether the intact polypeptide retains function, or even whether the epitope resides within an larger polypeptide.

25 30

### *Coupling to a sugar moiety*

The coupling of a sugar moiety, or “glycosylation,” can take place *in vivo* or *in vitro*.

Generally, glycosylation is classified as either “N-linked” or “O-linked” depending on the molecular nature of the attachment group. . N- and O- linked glycosylation sites can be

5 introduced according to the methods previously described herein, e.g., by doping or spiking with oligonucleotides corresponding to codons corresponding to N-linked and/or O-linked glycosylation sites. The terms “introduce” and “remove” as used in relation to a glycosylation site are primarily intended to mean substitution of amino acid residue(s), but may also mean insertion and deletion (without substitution), respectively. The  
10 introduction of an N-glycosylation site is conveniently achieved by introduction of one or more amino acid residues in the polypeptide in such a manner that a functional N-glycosylation site results. Analogously, an N-glycosylation site is removed by removal of one or more amino acid residues in the polypeptide in such a manner that an existing N-glycosylation site is destroyed.

15 In order to achieve *in vivo* coupling (i.e., *in vivo* glycosylation) of a polypeptide of interest which has been modified to introduce one or more glycosylation sites (see the section above entitled “Strategies for preparing a diversified population of nucleotide sequences”), the diversified population of nucleotide sequences must be inserted in a glycosylating, eucaryotic expression host. As a result of *in vivo* glycosylation attachment  
20 of sugar chains occurs *in vivo*, i.e., during posttranslational processing in a glycosylating cell used for expression of the polypeptide, e.g. by way of N-linked and/or O-linked glycosylation. The expression host cell can be selected from fungi-, insect- or animal cells, including human cells or from transgenic plant cells. In one embodiment the host cell is a mammalian cell, such as a Chinese hamster ovary (CHO) cell line, (e.g. CHO-  
25 K1; ATCC CCL-61), Green Monkey cell line (COS) (e.g. COS 1 (ATCC CRL-1650), COS 7 (ATCC CRL-1651)); mouse cell (e.g. NS/O), Baby Hamster Kidney (BHK) cell line (e.g. ATCC CRL-1632 or ATCC CCL-10), or human cell (e.g. HEK 293 (ATCC CRL-1573)), or any other suitable cell line, e.g., available from public depositories such as the American Type Culture Collection, Rockville, Maryland. Also, a mammalian  
30 glycosylation mutant cell line, such as CHO-LEC1, CHOL-LEC2 or CHO-LEC18 (CHO-LEC1: Stanley et al. Proc. Natl. Acad. USA 72, 3323-3327, 1975 and Grossmann et al., J. Biol. Chem. 270, 29378-29385, 1995, CHO-LEC18: Raju et al. J. Biol. Chem. 270, 30294-30302, 1995) may be used. Furthermore, an insect cell, such as a *Lepidoptera* cell

line, e.g. Sf9, a plant cell line or a yeast cell, e.g. *Saccharomyces cerevisiae*, *Pichia pastoris*, *Hansenula* spp. can be used.

Covalent *in vitro* coupling of glycosides to amino acid residues of a polypeptide of interest can be used to modify or increase the number or profile of sugar substituents. The  
5 *in vitro* coupling is normally performed in a conjugation step of the present invention. Typically, *in vitro* glycosylation is a synthetic glycosylation reaction, performed *in vitro*, normally involving covalently linking a sugar chain to an attachment group of a polypeptide, optionally using a cross-linking agent. Depending on the coupling reaction used, the sugar(s) can be attached to a) arginine and histidine, b) free carboxyl groups, c)  
10 free sulfhydryl groups such as those of cysteine, d) free hydroxyl groups such as those of serine, threonine, tyrosine or hydroxyproline, e) aromatic residues such as those of phenylalanine or tryptophan or f) the amide group of glutamine. Suitable methods are described, for example in WO 87/05330 and in Aplin et al., CRC Crit Rev. Biochem., pp. 259-306, 1981.

15 *In vitro* glycosylation utilizes available attachment groups, e.g., that have been introduced according to the methods of the invention. Covalent *in vitro* coupling of oligosaccharide or glycoside based molecules (such as dextran) to amino acid residues of the polypeptide may be performed, e.g. as described, for example in WO 87/05330, by Aplin et al., CRC Crit Rev. Biochem., pp. 259-306, 1981, and by Doebber et al., J. Biol.  
20 Chem., 257, pp2193-2199, 1982, the contents of which are incorporated herein by reference. For instance, Doebber et al. describe attachment of a synthetic Man3Lys2 glycopeptide to lysine residues by *in vitro* glycosylation. Furthermore, sugar moieties may be attached to the COOH group of an Asp, a Glu or the C-terminal amino acid residue of the polypeptide, to the SH group of a cysteine residue, to the aromatic group of  
25 a Phe, Tyr or Trp residue, To the guanidine group of an Arg residue, and to the imidazole ring of a His residue.

Furthermore, the *in vitro* coupling of sugar moieties or PEG to protein- and peptide-bound Gln-residues can be carried out by transglutaminases (TGases). Transglutaminases catalyse the transfer of donor amine-groups to protein- and peptide-  
30 bound Gln-residues in a so-called cross-linking reaction. The donor-amine groups can be protein- or peptide-bound e.g. as the  $\epsilon$ -amino-group in Lys-residues or it can be part of a small or large organic molecule. An example of a small organic molecule functioning as amino-donor in TGase-catalysed cross-linking is putrescine (1,4-diaminobutane). An example of a larger organic molecule functioning as amino-donor in TGase-catalysed



cross-linking is an amine-containing PEG (Sato et al., Biochemistry 35, 1996, 13072-13080).

TGases, in general, are highly specific enzymes, and not every Gln-residues exposed on the surface of a protein is accessible to TGase-catalysed cross-linking to amino-containing substances. In order to render a protein susceptible to TGase-catalysed cross-linking reactions, stretches of amino acid sequence known to function well as TGase substrates are included, e.g., by oligonucleotide spiking, as described above. Several amino acid sequences are known to be or to contain excellent natural TGase substrates e.g. substance P, elafin, fibrinogen, fibronectin,  $\alpha_2$ -plasmin inhibitor,  $\alpha$ -caseins, and  $\beta$ -caseins and may thus be inserted into and thereby constitute part of the amino acid sequence of a polypeptide to be modified in accordance with the invention. Furthermore, the *in vitro* coupling of sugar moieties or PEG to protein- and peptide-bound Gln-residues of a polypeptide of interest can be carried out by transglutaminases (TGases). Transglutaminases catalyse the transfer of donor amine-groups to protein- and peptide-bound Gln-residues in a so-called cross-linking reaction. The donor-amine groups can be protein- or peptide-bound e.g., as the  $\epsilon$ -amino-group in Lys-residues or it can be part of a small or large organic molecule. An example of a small organic molecule functioning as amino-donor in TGase-catalysed cross-linking is putrescine (1,4-diaminobutane). An example of a larger organic molecule functioning as amino-donor in TGase-catalysed cross-linking is an amine-containing PEG (Sato et al. (1996) Biochemistry 35, 13072-13080).

If desired, the nature and number of sugar moieties (and thus determination of an altered glycosylation pattern) of a conjugated polypeptide prepared in accordance with the invention can be determined by a number of different methods known in the art e.g. by lectin binding studies (Reddy et al., 1985, Biochem. Med. 33: 200-210; Cummings, 1994, Meth. Enzymol. 230: 66-86; Protein Protocols (Walker ed.), 1998, chapter 9); by reagent array analysis method (RAAM) sequencing of released oligosaccharides (Edge et al., 1992, Proc. Natl. Acad. Sci. USA 89: 6338-6342; Prime et al., 1996, J. Chrom. A 720: 263-274); by RAAM sequencing of released oligosaccharides in combination with mass spectrometry (Klausen, et al., 1998, Molecular Biotechnology 9: 195-204); or by combining proteolytic degradation, glycopeptide purification by HPLC, exoglycosidase degradations and mass spectrometry (Krogh et al, 1997, Eur. J. Biochem. 244: 334-342).

### *Conjugation to a lipophilic compound*

The polypeptide and lipophilic compound are conjugated to each other, either directly or using a linker. The lipophilic compound can be a natural compound such as a saturated or unsaturated fatty acid, a fatty acid diketone, a terpene, a prostaglandin, a vitamin, a carotinoid or steroid, or a synthetic compound such as a carboxylic acid, an alcohol, an amine and sulphonic acid with one or more alkyl-, aryl-, alkenyl- or other multiple unsaturated compounds. The conjugation between the polypeptide and the lipophilic compound, optionally through a linker can be done according to methods known in the art, e.g., as described by Bodanszky in *Peptide Synthesis*, John Wiley, New York, 1976 and in WO 96/12505.

### *Conjugation to a polymer molecule*

The polymer molecule to be coupled to the polypeptide can be any suitable polymer molecule, such as a natural or synthetic homo-polymer or heteropolymer, typically with a molecular weight in the range of 300-100,000 Da, such as 300-20,000 Da, more preferably in the range of 500-10,000 Da, even more preferably in the range of 500-5000 Da.

Examples of homo-polymers include a polyol (i.e. poly-OH), a polyamine (i.e. poly-NH<sub>2</sub>) and a polycarboxylic acid (i.e. poly-COOH). A hetero-polymer is a polymer, which comprises one or more different coupling groups, such as, e.g., a hydroxyl group and an amine group.

Examples of suitable polymer molecules include polymer molecules selected from the group consisting of polyalkylene oxide (PAO), including polyalkylene glycol (PAG), such as polyethylene glycol (PEG) and polypropylene glycol (PPG), branched PEGs, polyvinyl alcohol (PVA), poly-carboxylate, poly-(vinylpyrrolidone), polyethylene-co-maleic acid anhydride, polystyrene-co-malic acid anhydride, dextran including carboxymethyl-dextran, or any other biopolymer suitable for altering immunogenicity and/or increasing functional *in vivo* half-life and/or serum half-life. Another example of a polymer molecule is human albumin or another abundant plasma protein. Generally, polyalkylene glycol-derived polymers are biocompatible, non-toxic, non-antigenic, non-immunogenic, have various water solubility properties, and are easily excreted from living organisms.

PEG is the preferred polymer molecule to be used, since it has only few reactive groups capable of cross-linking compared, e.g., to polysaccharides such as dextran, and the like. In particular, monofunctional PEG, e.g. methoxypolyethylene glycol (mPEG), is of interest

since its coupling chemistry is relatively simple (only one reactive group is available for conjugating with attachment groups on the polypeptide). Consequently, the risk of cross-linking is eliminated, the resulting polypeptide conjugates are more homogeneous and the reaction of the polymer molecules with the polypeptide is easier to control.

5           To effect covalent attachment of the polymer molecule(s) to the polypeptide, the hydroxyl end groups of the polymer molecule must be provided in activated form, i.e. with reactive functional groups. Suitably activated polymer molecules are commercially available, e.g. from Shearwater Polymers, Inc., Huntsville, AL, USA. Alternatively, the polymer molecules can be activated by conventional methods known in the art, e.g. as  
10 disclosed in WO 90/13540. Specific examples of activated linear or branched polymer molecules for use in the present invention are described in the Shearwater Polymers, Inc. 1997 and 2000 Catalogs (Functionalized Biocompatible Polymers for Research and pharmaceuticals, Polyethylene Glycol and Derivatives, incorporated herein by reference). Specific examples of activated PEG polymers include the following linear PEGs: NHS-  
15 PEG (e.g. SPA-PEG, SSPA-PEG, SBA-PEG, SS-PEG, SSA-PEG, SC-PEG, SG-PEG, and SCM-PEG), and NOR-PEG), BTC-PEG, EPOX-PEG, NCO-PEG, NPC-PEG, CDI-PEG, ALD-PEG, TRES-PEG, VS-PEG, IODO-PEG, and MAL-PEG, and branched PEGs such as PEG2-NHS and those disclosed in US 5,932,462 and US 5,643,575, both of which references are incorporated herein by reference. Furthermore, the following publications,  
20 incorporated herein by reference, disclose useful polymer molecules and/or PEGylation chemistries: US 5,824,778, US 5,476,653, WO 97/32607, EP 229,108, EP 402,378, US 4,902,502, US 5,281,698, US 5,122,614, US 5,219,564, WO 92/16555, WO 94/04193, WO 94/14758, WO 94/17039, WO 94/18247, WO 94/28024, WO 95/00162, WO 95/11924, WO95/13090, WO 95/33490, WO 96/00080, WO 97/18832, WO 98/41562,  
25 WO 98/48837, WO 99/32134, WO 99/32139, WO 99/32140, WO 96/40791, WO 98/32466, WO 95/06058, EP 439 508, WO 97/03106, WO 96/21469, WO 95/13312, EP 921 131, US 5,736,625, WO 98/05363, EP 809 996, US 5,629,384, WO 96/41813, WO 96/07670, US 5,473,034, US 5,516,673, EP 605 963, US 5,382,657, EP 510 356, EP 400 472, EP 183 503 and EP 154 316.

30           The conjugation of the polypeptide and the activated polymer molecules is conducted by use of any conventional method, e.g. as described in the following references (which also describe suitable methods for activation of polymer molecules): R.F. Taylor, (1991), "Protein immobilisation. Fundamental and applications", Marcel Dekker, N.Y.; S.S. Wong, (1992), "Chemistry of Protein Conjugation and Crosslinking", CRC Press, Boca

Raton; G.T. Hermanson et al., (1993), "Immobilized Affinity Ligand Techniques", Academic Press, N.Y.). The skilled person will be aware that the activation method and/or conjugation chemistry to be used depends on the attachment group(s) of the polypeptide as well as the functional groups of the polymer (e.g. being amino, hydroxyl, carboxyl, aldehyde or sulfhydryl). The PEGylation can be directed towards conjugation to all available attachment groups on the polypeptide or a carbohydrate molecule linked thereto (i.e. such attachment groups that are exposed at the surface of the polypeptide) or can be directed towards specific attachment groups, e.g. the N-terminal amino group (US 5,985,265). Furthermore, the conjugation can be achieved in one step or in a stepwise manner (e.g. as described in WO 99/55377).

Furthermore, the PEGylation step of a method of the invention can be designed so as to introduce a number of polymer molecules having a molecular weight, which number and weight are suitable for the polypeptide of interest and for achieving the desired effect of the PEGylation. For instance, if the primary purpose of the conjugation is to achieve a conjugate having a high molecule weight (e.g. to reduce renal clearance) it is usually desirable to conjugate as few high Mw polymer molecules as possible to obtain the desired molecular weight. When a substantial decrease of immunogenicity is desirable this can be obtained by use of a sufficiently high number of low molecular weight polymer (e.g. with a molecular weight of about 5,000 Da) to effectively shield all or most epitopes of the polypeptide. For instance, 2-8, such as 3-6 such polymers can be used.

In particular, extensive PEGylation can be employed when it is not critical to maintain a close to intact function of the polypeptide, since a normally observed drawback of too extensive PEGylation is that the function of the modified polypeptide is reduced. If a nearly intact function of the polypeptide of interest is desirable as well, the extensive PEGylation is conveniently performed according to the embodiment of the invention wherein a functional site of the polypeptide is blocked during PEGylation. If, on the other hand, it is critical to maintain a high function of the polypeptide of interest and less critical to obtain a substantially increased functional *in vivo* half-life and/or altered immunogenicity, the PEGylation should be designed so as to allow for a less extensive PEGylation.

In connection with conjugation to only a single attachment group on the protein (as described in US 5,985,265), it can be advantageous that the polymer molecule, which can be linear or branched, has a high molecular weight, e.g. about 20 kDa.

Normally, the polymer conjugation is performed under conditions aiming at reacting all available polymer attachment groups with polymer molecules. Typically, the molar ratio of activated polymer molecules to polypeptide is 200-1, such as 100-1 and preferably 10-1 or 5-1 to obtain optimal reaction. However, also equimolar ratios of polypeptide to polymer  
5 may be used.

It is also contemplated according to the invention to couple the polymer molecules to the polypeptide through a linker. Suitable linkers are well known to the skilled person. A preferred example is cyanuric chloride (Abuchowski et al., (1977), J. Biol. Chem., 252, 3578-3581; US 4,179,337; Shafer et al., (1986), J. Polym. Sci. Polym. Chem. Ed., 24,  
10 375-378.

Subsequent to the conjugation residual activated polymer molecules are blocked according to methods known in the art, e.g., by addition of primary amine to the reaction mixture.

#### 15 *Coupling to an organic derivatizing agent*

Covalent modification of the polypeptide of interest can be performed by reacting (an) attachment group(s) of the polypeptide of interest with an organic derivatizing agent. Suitable derivatizing agents and methods are well known in the art. For example, cysteinyl residues most commonly are reacted with  $\alpha$ -haloacetates (and corresponding  
20 amines), such as chloroacetic acid or chloroacetamide, to give carboxymethyl or carboxyamidomethyl derivatives. Cysteinyl residues also are derivatized by reaction with bromotrifluoroacetone,  $\alpha$ -bromo- $\beta$ -(4-imidazolyl)propionic acid, chloroacetyl phosphate, N-alkylmaleimides, 3-nitro-2-pyridyl disulfide, methyl 2-pyridyl disulfide, p-chloromercuribenzoate, 2-chloromercuri-4-nitrophenol, or chloro-7-nitrobenzo-2-oxa-1,3-  
25 diazole. Histidyl residues are derivatized by reaction with diethylpyrocarbonate at pH 5.5-7.0 because this agent is relatively specific for the histidyl side chain. Para-bromophenacyl bromide also is useful; the reaction is preferably performed in 0.1 M sodium cacodylate at pH 6.0. Lysinyl and amino terminal residues are reacted with succinic or other carboxylic acid anhydrides. Derivatization with these agents has the  
30 effect of reversing the charge of the lysinyl residues. Other suitable reagents for derivatizing  $\alpha$ -amino-containing residues include imidoesters such as methyl picolinimide; pyridoxal phosphate; pyridoxal; chloroborohydride; trinitrobenzenesulfonic acid; O-methylisourea; 2,4-pentanedione; and transaminase-catalyzed reaction with glyoxylate. Arginyl residues are modified by reaction with one or

several conventional reagents, among them phenylglyoxal, 2,3-butanedione, 1,2-cyclohexanedione, and ninhydrin. Derivatization of arginine residues requires that the reaction be performed in alkaline conditions because of the high pKa of the guanidine functional group. Furthermore, these reagents can react with the groups of lysine as well  
5 as the arginine epsilon-amino group. Carboxyl side groups (aspartyl or glutamyl) are selectively modified by reaction with carbodiimides ( $R-N=C=N-R'$ ), where R and R' are different alkyl groups, such as 1-cyclohexyl-3-(2-morpholinyl-4-ethyl) carbodiimide or 1-ethyl-3-(4-azonia-4,4-dimethylpentyl) carbodiimide. Furthermore, aspartyl and glutamyl residues are converted to asparaginyl and glutaminyl residues by reaction with  
10 ammonium ions.

#### Blocking of functional site

It has been reported that excessive polymer conjugation often results in a loss of activity of the polypeptide in question. This problem can be eliminated, e.g., by removal of  
15 attachment groups located at the active site (according to one embodiment of the present invention discussed above in the section entitled "Strategies for creating a diversified population of nucleotide sequences) or by blocking the functional site prior to conjugation. This latter strategy constitutes a further embodiment of the invention. More specifically, in accordance with this embodiment the conjugation between the polypeptide  
20 and the non-polypeptide moiety is conducted under conditions where the functional site of the polypeptide is blocked by a helper molecule capable of binding to the functional site of the polypeptide. Preferably, the helper molecule is one, which specifically recognizes the functional site of the polypeptide. The helper molecule can, e.g., be a low molecular weight ligand, a receptor or the like.

25 The polypeptide is allowed to interact with the helper molecule before effecting conjugation. This ensures that the functional site of the polypeptide is shielded or protected and consequently unavailable for derivatization by the non-polypeptide moiety such, as a polymer. Following its elution from the helper molecule, the conjugate between the non-polypeptide moiety and the polypeptide can be recovered with at least a partially  
30 preserved functional site.

For instance, when the polypeptide of interest is an antibody the helper molecule can be, e.g., an antigen or an anti-idiotypic antibody. When the polypeptide of interest is a cytokine the helper molecule can be a receptor or a specific antibody. When the polypeptide of interest is an antigen the helper molecule can be an antibody. When the

polypeptide of interest is an enzyme the helper molecule can be an enzyme inhibitor or an antibody. When the polypeptide of interest is a ligand the helper molecule can be a receptor or antibody. When the polypeptide of interest is a receptor the helper molecule can be a ligand or antibody. Specific examples of pairs of polypeptide of interest and

5 helper molecule include the following:

Streptokinase or staphylokinase – plasminogen; hirudin – thrombin; a hormone – the specific receptor; a growth factor - a growth factor receptor; a cytokine – the corresponding cytokine receptor; a fibrinolytic enzyme such as pro-urokinase, urokinase or tPA - benzamidine or a derivative thereof; a heparin-binding protein such as a growth  
10 factor – heparin, a heparin-like molecule or a heparin derivative, in particular one with a low molecular weight and a negative charge; a DNA binding protein - DNA or an oligonucleotide.

In some instances it can be desirable to preserve the biological activities mediated by two or more separate functional sites of the polypeptide of interest. In such cases both  
15 biological activities can be preserved through the use of two or more specific binders each recognizing one of the two or more functional sites.

The subsequent conjugation of the polypeptide having a blocked functional site to a polymer, a lipophilic compound, a sugar moiety, an organic derivatizing agent or any other compound is conducted in the normal way, e.g., as described in the sections above  
20 entitled “Conjugation to ....”.

Irrespective of the nature of the helper molecule to be used to shield the functional site of the polypeptide of interest from conjugation, it is desirable that the helper molecule is free from or comprises only a few attachment groups for the non-polypeptide moiety of choice in part(s) of the molecule, where the conjugation to such  
25 groups will hamper the desorption of the conjugated polypeptide from the helper molecule. Hereby, selective conjugation to attachment groups present in non-shielded parts of the polypeptide can be obtained and it is possible to reuse the helper molecule for repeated cycles of conjugation. For instance, if the non-polypeptide moiety is a polymer molecule such as PEG, which has the epsilon amino group of a lysine or N-terminal  
30 amino acid residue as an attachment group, it is desirable that the helper molecule is substantially free from conjugatable epsilon amino groups, preferably free from any epsilon amino groups. Accordingly, in a preferred embodiment the helper molecule is a protein or peptide capable of binding to the functional site of the polypeptide, which

protein or peptide is free from any conjugatable attachment groups for the non-polypeptide moiety of choice.

Of particular interest in connection with the embodiment of the present invention wherein the polypeptide conjugates are prepared from a diversified population of  
5 nucleotide sequences encoding a polypeptide of interest, the blocking of the functional group is effected in microtiter plates prior to conjugation, for instance, by plating the expressed polypeptide variant in a microtiter plate containing an immobilized blocking group such as a receptor, an antibody or the like.

In a further embodiment the helper molecule is first covalently linked to a solid  
10 phase such as column packing materials, for instance Sephadex or agarose beads, or a surface, e.g. reaction vessel. Subsequently, the polypeptide is loaded onto the column material carrying the helper molecule and conjugation carried out according to methods known in the art, e.g. as described in the sections above entitled "Conjugation to ....". This procedure allows the polypeptide conjugate to be separated from the helper molecule  
15 by elution. The polypeptide conjugate is eluted by conventional techniques under physico-chemical conditions that do not lead to a substantive degradation of the polypeptide conjugate. The fluid phase containing the polypeptide conjugate is separated from the solid phase to which the helper molecule remains covalently linked. The separation can be achieved in other ways: For instance, the helper molecule can be  
20 derivatised with a second molecule (e.g. biotin) that can be recognized by a specific binder (e.g. streptavidin). The specific binder can be linked to a solid phase thereby allowing the separation of the polypeptide conjugate from the helper molecule-second molecule complex through passage over a second helper-solid phase column which will retain, upon subsequent elution, the helper molecule-second molecule complex, but not  
25 the polypeptide conjugate. The polypeptide conjugate can be released from the helper molecule in any appropriate fashion. Deprotection can be achieved by providing conditions in which the helper molecule dissociates from the functional site of the polypeptide of interest to which it is bound. For instance, a complex between an antibody to which a polymer is conjugated and an anti-idiotypic antibody can be dissociated by  
30 adjusting the pH to an acid or alkaline pH.

#### Conjugation of a tagged polypeptide

In an alternative embodiment the polypeptide of interest is expressed, as a fusion protein, with a tag, i.e., an amino acid sequence or peptide stretch made up of typically 1-30, such



as 1-20 amino acid residues. Besides allowing for fast and easy purification, the tag is a convenient tool for achieving conjugation between the tagged polypeptide of interest and the non-polypeptide moiety. In particular, the tag can be used for achieving conjugation in microtiter plates or other carriers, such as paramagnetic beads, to which the tagged polypeptide can be immobilised via the tag. The conjugation to the tagged polypeptide of interest in, e.g., microtiter plates has the advantage that the tagged polypeptide can be immobilised in the microtiter plates directly from the culture broth (in principle without any purification) and subjected to conjugation. Thereby, the total number of process steps (from expression to conjugation) can be reduced. Furthermore, the tag can function as a spacer molecule ensuring an improved accessibility to the immobilised polypeptide to be conjugated. The conjugation using a tagged polypeptide can be to any of the non-polypeptide moieties disclosed herein, e.g. to a polymer molecule such as PEG. The identity of the specific tag to be used is not critical as long as the tag is capable of being expressed with the polypeptide and is capable of being immobilised on a suitable surface or carrier material. A number of suitable tags are commercially available, e.g. from Unizyme Laboratories, Denmark. For instance, the tag can any of the following sequences:

His-His-His-His-His-His

Met-Lys-His-His-His-His-His

20 Met-Lys-His-His-Ala-His-His-Gln-His-His

Met-Lys-His-Gln-His-Gln-His-Gln-His-Gln-His-Gln

(all available from Unizyme Laboratories, Denmark)

or any of the following:

EQKLI SEEDL (a C-terminal tag described in Mol. Cell. Biol. 5:3610-16, 1985)

25 DYKDDDDK (a C- or N-terminal tag)

YPYDVPDYA

Antibodies against the above tags are commercially available, e.g. from ADI, Aves Lab and Research Diagnostics.

A convenient method for using a tagged polypeptide for PEGylation is given in the Materials and Methods section below.

The subsequent cleavage of the tag from the polypeptide can be achieved by use of commercially available enzymes.

*Method of avoiding conjugation of the N-terminal amino acid residue*

In a further aspect the invention relates to a generally applicable method for avoiding conjugation at the N-terminal amino acid residue of a polypeptide of interest, e.g. any of those mentioned in the section entitled "Polypeptide of interest" and preferably a therapeutically active polypeptide such as a cytokine or a hormone or an industrially useful polypeptide such as an enzyme. More specifically, this aspect relates to a method of preparing a polypeptide conjugate comprising a polypeptide of interest and a non-polypeptide moiety, the non-polypeptide moiety being able to attach to the N-terminal amino acid residue of the polypeptide and the polypeptide having an N-terminal Gln residue, which method comprises derivatizing the N-terminal Gln residue with glutamine cyclotransferase to obtain a pyro Glu residue, and subjecting the resulting derivatized polypeptide to conjugation. The method according to this aspect finds particular interest where conjugation to an N-terminal amino acid residue is undesirable. The pyro Glu residue cannot be conjugated and thus N-terminal conjugation is avoided.

The non-polypeptide moiety can be any of those described in the section entitled "Conjugation to a polymer molecule", and is preferably polyethylene glycol (PEG). The conjugation can be achieved as described in that section.

The derivatization of the N-terminal Gln is done with glutamine cyclotransferase in accordance with established techniques, e.g. as recommended by the manufacturer. The enzyme can be purchased from Unizyme, Denmark.

Normally, the N-terminal Gln residue has been introduced into the polypeptide sequence, either by substitution of the N-terminal residue of the parent polypeptide, or by addition of the Gln residue to said N-terminal residue. The substitution or addition can be accomplished by methods known in the art.

The method according to this aspect normally further comprises removing the pyro Glu residue, conveniently by use of pyroglutamyl aminopeptidase in accordance with established techniques. The enzyme is, e.g., available from Unizyme, Denmark. Removal of the pyro Glu residue is relevant, when the presence of such residue impairs the function of the conjugate. Furthermore, the presence of such residue in conjugates intended for therapeutic use is normally undesirable.

### Screening

It will be understood that the screening for improved properties, such as function, immunogenicity and/or functional *in vivo* half-life is designed on the basis of the desired result to achieve. If, for instance, a method of the invention is used to alter the

immunogenicity of an otherwise functional polypeptide of interest the screening step will primarily be designed so as to screen for altered, i.e., reduced or increased immunogenicity, whereas no screening for function or functional *in vivo* half-life is conducted. Typically, it is desirable to employ high throughput screening methods in conjunction with the methods of the invention. High throughput is typically in excess of 100, frequently in excess of 1000, and often in excess of 10,000 samples per day. Numerous formats for accomplishing high throughput screening are known in the art. Among the more common formats are microtiter plates, pin arrays, bead arrays, membranes, filters and microfluidic devices.

One standard format for the performance of high throughput assays is microtiter plates. Microtiter plates with 96, 384 or 1536 wells are widely available, however other numbers of wells, e.g., 3456 and 9600 are also used. In general, the choice of microtiter plates is determined by the handling and/or analytical device to be used, e.g., automated loading and robotic handling systems. Exemplary systems include the ORCA™ system from Beckman-Coulter, Inc. (Fullerton, CA) and the Zymate systems from Zymark Corporation (Hopkinton, MA).

Alternatively, other formats such as “chip” or pin arrays, or formats involving immobilization of one or more assay component on a solid support such as a membrane or filter, e.g., nylon, nitrocellulose, and the like, are employed in high throughput assays useful in the context of the present invention. In addition, numerous assays useful in detecting proteins, or cells expressing proteins, with desirable properties can be performed in microfluidic devices such as the LabMicrofluidic device™ high throughput screening system (HTS) by Caliper Technologies Corp., Mountain View, CA, or the HP/Agilent technologies Bioanalyzer using LabChip™ technology by Caliper Technologies Corp. See, also, [www.calipertech.com](http://www.calipertech.com).

#### *Screening for function*

As indicated above the function/functions for which screening is to be performed depend on the nature of the polypeptide of interest. Typically, the function to be screened for is selected from the group consisting of activity, affinity, potency, efficiency, specificity and selectivity. For instance, when the polypeptide is an enzyme, the function to be screened for will typically be selected from the group consisting of enzymatic activity, substrate specificity, substrate affinity, temperature optimum, pH optimum, thermostability, pH tolerance, tolerance towards components with which the enzyme is in contact under its

normal use, enzyme kinetic parameters such as  $V_{max}$  or  $K_m$ , etc. When the polypeptide of interest is an antibody, the function to be screened for is typically the antibody's ability to bind or the affinity for an antigen or epitope. When the polypeptide of interest is a hormone or an interleukin the function to be screened for is typically the receptor affinity, 5 receptor signalling capability, activity, specificity, potency or selectivity. When the polypeptide of interest is a regulatory protein the function to be screened for is typically affinity, specificity or selectivity. The screening can be conducted according to principles well known in the art for screening for the function in question.

Conveniently, the screening for function is conducted in microtiter plates, in 10 particular in the plates containing the polypeptide conjugate resulting from the conjugation step of a method of the invention. Preferably, the screening is a high throughput screening. In the context of the present application "microtiter plates" are to be understood broadly to comprise not only microtiter plates in its conventional meaning, but also chips and other solid phases suitable for screening a high number of samples in a 15 short time, as described above. In accordance with the specific embodiment of the invention wherein a functional site of the polypeptide of interest is blocked during the polypeptide conjugation step, the screening for function can be omitted in that only functional polypeptides capable of binding to the blocking group will be conjugated to the non-polypeptide moiety, such as a polymer.

20

#### *Screening for altered immunogenicity*

Conveniently, the screening for altered immunogenicity is performed by contacting the polypeptide conjugate with an antibody recognizing the non-conjugated polypeptide and detecting the amount of antibody reacting with the conjugate. The detection of the amount 25 of antibody is done in accordance with standard immunochemistry methods known in the art. For instance, the detection method is based on the use of secondary antibody, such as an anti-human antibody, conjugated to an enzyme catalyzing a measurable reaction with subsequent detection of the enzyme activity. The enzyme can, e.g., be horseradish peroxidase. The detection method can also be based on a method wherein the antibody 30 and/or the secondary antibody is/are labeled with a fluorescent probe. Furthermore, the secondary antibody can be labeled with a radioactive probe such as I-125 or H-3. The screening for altered immunogenicity is conveniently performed in microtiter plates.

### *Screening for function and altered immunogenicity*

In a highly preferred embodiment the screening for function and altered, in particular reduced immunogenicity is performed simultaneously. More specifically, the screening can be conducted in parallel, i.e. subjecting the population of polypeptide conjugates  
5 resulting from the conjugation step of a method of the invention to parallel screening for function and immunogenicity, respectively, and selecting polypeptide conjugates which have altered immunogenicity and a measurably function relative to the polypeptide of interest. Alternatively, the screening for function and altered immunogenicity can be performed as one screening, when a functional site of the polypeptide of interest is  
10 blocked as described in the section entitled "Blocking of a functional site" (thereby inherently resulting in a functional polypeptide) and the screening to be conducted is for altered immunogenicity as described above.

Preferably, the simultaneous screening for function and altered immunogenicity is done in microtiterplates. An advantage of using microtiter plates is that the screening can  
15 be performed as a high throughput screening. In a highly preferred embodiment of a method of the present invention the polymer conjugation and the screening are performed in the same microtiter plates. This ensures an efficient high throughput screening procedure.

### *20 Secondary screening*

In addition to or as an alternative to the above primary screening procedures a secondary screening for function or immunogenicity is normally performed.

A secondary screening for function is conveniently conducted by isolating the polypeptide conjugate and subjecting the isolated conjugate to a suitable test for the  
25 function in question. Relevant functions for different types of polypeptides of interest are exemplified in the section above termed "Screening for function". The secondary screening can be conducted in accordance with methods known in the art for assessing the function in question.

A secondary screening for altered immunogenicity is conveniently conducted by  
30 injecting an animal subcutaneously with the modified polypeptide or polypeptide conjugate and comparing the response with the response of the corresponding unmodified or non-conjugated polypeptide of interest. A number of *in vitro* animal models exist for assessment of the immunogenic potential of polypeptides. Some of these models give a suitable basis for hazard assessment in man. Suitable models include mice, rabbit and hamster model. One

model seeks to identify the immune response in the form of the IgG response in Balb/C mice being injected subcutaneously with a modified polypeptide or polypeptide conjugate and the unmodified or non-conjugated polypeptide of interest, respectively. For Balb/C mice the IgG response gives a good indication of the immunogenic potential of polypeptides. Also other  
5 animal models can be used for assessment of the immunogenic potential.

A polypeptide having “altered immunogenicity” according to the invention gives rise to a decreased or increased immune reaction, e.g., reflected in reduced or increased amount of produced antibodies in comparison to the polypeptide of interest.

#### 10 *Screening for increased functional in vivo half-life*

The screening for increased functional *in vivo* half-life can be conducted in accordance with methods known in the art for assessing functional *in vivo* half-life. For example, BALB/c mice are injected intravenously, intramuscularly or subcutaneously with a suitable amount of the modified polypeptide to be analysed and blood samples collected  
15 at suitable time intervals in order to be able to determine the functional *in vivo* half-life of the polypeptide. Examples of suitable methods are described by He et al., Life Sciences, Vol. 64, No. 14, pp. 1163-1175, 1999 and Pettit et al., the Journal of Biological Chemistry, Vol. 272, No. 4, p. 2312-2318, 1997.

#### 20 Analysis of polypeptide conjugates selected in a method of the invention

Once a suitable modified polypeptide, in particular a polypeptide conjugate, constructed according to the invention has been selected in a screening step of a method of the invention the nucleotide sequence encoding the polypeptide part of the conjugate is isolated and used for expression of larger amounts of the polypeptide (see below). The  
25 amino acid sequence of the resulting polypeptide is determined and the polypeptide is subjected to conjugation in a larger scale. Subsequently, the polypeptide conjugate is assayed with respect to immunogenicity and/or functional *in vivo* half-life. The polypeptide part of the conjugate or the polypeptide resulting from the method according to the first aspect of the invention is termed “modified polypeptide”.

30

#### Preparing a polypeptide conjugate resulting from a method of the invention

Once the modified polypeptide, in particular the polypeptide conjugate, has been analysed it can be produced in a larger scale, such as for commercial purposes, using methods known in the art.

The modified polypeptide is conveniently produced by recombinant expression technology known in the art. In brief, a nucleotide sequence encoding the polypeptide is inserted into a suitable expression vector with which a suitable host cell is subsequently transformed or transfected. Alternatively, the nucleotide sequence is directly inserted into  
5 the host cell. In the host cell the nucleotide sequence encoding the polypeptide is operably linked to all the control sequences required for expression of the sequence. The nucleotide sequence can be single- or double-stranded and can include, but is not limited to, DNA, cDNA, and recombinant nucleic acid sequences.

The term "control sequences" is defined herein to include all components which  
10 are necessary or advantageous for the expression of the modified polypeptide. Each control sequence can be native or foreign to the nucleic acid sequence encoding the polypeptide. Such control sequences include, but are not limited to, a leader, polyadenylation sequence, propeptide sequence, promoter, enhancer or upstream activating sequence, signal peptide sequence, and transcription terminator. At a minimum,  
15 the control sequences include a promoter, and transcriptional and translational stop signals. The choice of host cell will depend, to a large extent, on the nature of the polypeptide to be produced, including its origin, the quantity of polypeptide required, and the intended use of the polypeptide. Furthermore, any need for posttranslational modification by the host will influence the choice of host. Examples of host cells that can  
20 be used include mammalian, insect or microbial cells, such as bacterial, yeast or fungal cells. Suitable expression systems which are generally known by the skilled person include a mammalian expression system based on CHO, BHK or COS cells (see *in vivo* glycosylation section above), an insect cell expression system such as SF9 cells, a yeast expression system based on *Saccharomyces cerevisiae*, *Pichia* such as *P. pastoris* or *P.*  
25 *methanolica* or *Hansenula*, such as *H. polymorpha*, a bacterial expression system based on *Bacillus*, such as *B. subtilis*, or *Escherichia coli*, and a fungal expression system based on *Aspergillus*, *Fusarium* or *Trichoderma*. Transformation of any of these cells with the nucleotide sequence encoding the modified polypeptide is performed in accordance with well-known methods for such transformation.

30 The recombinant production of the polypeptide is normally achieved by cultivating the resulting host cell containing a nucleotide sequence encoding the modified polypeptide under conditions conducive for the production of the polypeptide, and recovering the polypeptide. If the polypeptide is produced as an extracellular product it is normally recovered directly from the medium. If it is produced as an intracellular

polypeptide it is normally recovered after disruption of the cells resulting from the cultivation. Subsequent to being recovered the polypeptide can be subjected to further purification or other treatment.

Subsequent to recovery and possible other treatment, the polypeptide is subjected  
5 to conjugation to the non-polypeptide moiety according to methods known in the art. The conjugation is carried out under conditions ensuring the same degree and nature of conjugation as that found in the polypeptide molecule being selected in a method of the invention.

In the present application reference has been made to a number of publications,  
10 the contents of which should be considered to be incorporated herein by reference.

In the following non-limiting examples methods of the present invention are exemplified using staphylokinase as an illustrative example of a polypeptide of interest. The examples should not, in any manner, be construed as limiting the generality of the present invention.

15

## EXAMPLES

## MATERIALS

20 Plasmin substrate S-2251/H-D-Val-Leu-Lys-pNA from Chromogenix

pET12a expression vector (Novagen, Inc., Studier et al. Methods of Enzymology 185, 60-89, 1990).

25 The *E. coli* strains BL21(DE3), B834(DE3), AD494(DE3) or BLR(DE3) (Novagen, Inc., Studier et al. Methods of Enzymology 185, 60-89, 1990)

## Media

### LB medium:

30 Per liter:

10 g Bacto tryptone

5 g yeast extract

10 g NaCl

Adjust pH to 7.5 and autoclave.



## METHODS

### Construction of a protein sequence family

- 5 The construction of a protein sequence family from a single protein amino acid sequence can be performed in a number of ways. For instance, the sequence family can be provided from a publicly available pre-constructed protein sequence family, e.g. the PFAM families database (<http://pfam.wustl.edu/>)(*Nucleic Acids Res* 1999 Jan 1;27(1):260-2) version 4.0 or the PROSITE data base Hofmann K., Bucher P., Falquet L., Bairoch A.*The*  
10 *PROSITE database, its status in 1999* *Nucleic Acids Res.* 27:215-219(1999). Furthermore, the protein sequence family can be provided from recursive searches in protein sequence databases like SWISS-PROT or TrEMBL Bairoch A., Apweiler R. *The SWISS-PROT protein sequence data bank and its supplement TrEMBL in 1999* *Nucleic Acids Res.* 27:49-54(1999) using well established sequence search/comparison algorithms  
15 like FASTA (Pearson W.R. and Lipman D.J. (1981) *Proc. Natl. Acad. Sci. U.S.A.* 85. 2444-2448), BLAST (Altschul, S.F. *et.al.* (1997) *Nucleic Acids Res.* 25. 3389-3402), PSI-BLAST (Altschul, Stephen F., Thomas L. Madden, Alejandro A. Schäffer, Jinghui Zhang, Zheng Zhang, Webb Miller, and David J. Lipman (1997), "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", *Nucleic Acids Res.*  
20 25:3389-3402.) or from searches in nucleotide sequence data bases like EMBL (Guenther Stoesser\*, Mary Ann Tuli, Rodrigo Lopez and Peter Sterk, *Nucleic Acids Research*, 1999, 27(1):18-24) or GENE BANK (Benson DA, Boguski MS, Lipman DJ, Ostell J, Ouellette BF, Rapp BA, Wheeler DL. *Nucleic Acids Res* 1999, 27(1):12-17) using equally well established search algorithms. An overview of these methods can be found in *Trends*  
25 *Guide to Bioinformatics* (1998) Elsevier Science. The sequences of the members of the *protein sequence family* can be aligned using standard software, e.g. CLUSTALW, version 1.74 (Thompson, J.D., Higgins, D.G. and Gibson, T.J. (1994) CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, positions-specific gap penalties and weight matrix choice, *Nucleic Acids*  
30 *Research*, 22:4673-4680).

### Building a model structure

A model structure can easily be constructed by the skilled person on the basis of the known three-dimensional structure of another member of the polypeptide sequence family

to which the polypeptide of interest belongs. In order to be able to construct a model structure it is normally desirable that the polypeptide of interest displays at least 30% sequence identity with the polypeptide with the known three-dimensional structure. The model structure can be constructed using any suitable software known in the art, such as, 5 for example, the software Modeller (Andrej Sali, Roberto Sánchez, Azat Badretdinov, András Fiser, and Eric Feyfant, The Rockefeller University, 1230 York Avenue, New York, NY 10021-6399, USA) or the software WHAT IF: *A molecular modeling and drug design program* (G.Vriend, J. Mol. Graph. (1990) 8, 52-56).

## 10 Methods for use in determining target locii for modification of a polypeptide of interest

### *A: Analysis of the polypeptide structure or sequence*

#### *1. Accessible surface area:*

15 From a three-dimensional structure of the polypeptide of interest (e.g. X-ray, NMR or model structure) the surface accessibility of the individual atoms can be computed using state of the art software, e.g. NACCESS (c) S. Hubbard and J. Thornton 1992-6, <http://sjh.bi.umist.ac.uk/naccess.html>, What If (see reference above) or similar software, e.g. Biosym/Insight II. These methods typically use a probe-size of 1.4Å and define the 20 *Accessible Surface Area (ASA)* as the area formed by the center of the probe. Prior to this calculation all water molecules, all hydrogen atoms and other atoms not directly related to the protein (such as unrelated metal ions, co-factors and the like) are removed from the coordinate set.

#### 25 *2. Determine residues potentially exposed to the surface:*

In order to determine residues potentially exposed to the surface of the polypeptide of interest the following steps are performed:

If a structure or a model structure is available residues are considered to be exposed to the surface if any part of any side chain atom (*i.e.* excluding the backbone atoms N, C, CA, 30 and O for all amino acid residues except Gly) is in contact with the solvent. If the residue is a Glycine (Gly) the residue is considered to be exposed to the surface if the CA atom has any contact with the solvent. In this respect contact with the solvent is defined as any non-zero accessible surface area (ASA).

If a protein sequence family comprising the polypeptide of interest is available, any residue equivalent to a hydrophilic residue (Asp, Glu, His, Lys, Asn, Gln, Arg, Ser, Thr, Tyr) or Gly in any of the other members of the protein sequence family, the amino acid sequence of which has at least 40% identity to the amino acid sequence of the polypeptide of interest, is regarded as potentially exposed to the surface.

If a structure, a model structure or a protein sequence family is not available any hydrophilic residue (see above) and Gly are regarded as potentially exposed to the surface.

In the case where a structure of the complete sequence is not available but a structure of a part of the sequence is available a combination of a), b) and c) is applied, i.e. a) is used for the part where a structure is available and b) and/or c) is used for the remaining part.

*B: Selection of amino acid residues or regions to be mutagenized*

The method for selection of residues or regions to be mutagenized comprises the following steps:

- 1: Construct a protein sequence family on the basis of the amino acid sequence of the polypeptide of interest
- 2: Determine residues potentially exposed to the surface (see section A above)
- 3: If a three-dimensional structure is available:
  - a) Determine the distance from the CB in each residue (in the case of Gly from the CA) to CB of all amino acid residues containing an attachment group, such as a polymer attachment group.  
Determine the distance from the CB in each residue (in the case of Gly from the CA) to the (polymer) attachment group of all residues of the type to be modified (NZ in the case of a Lys, CG in the case of an Asp, CE in the case of a Glu, N for the N-terminal residue and the C of the C-terminal residue, etc.).
  - c) Determine the shortest distance from the (polymer) attachment group of each amino acid residue containing such group to the (polymer) attachment group of any other amino acid residue containing such group.

4: Determine the residues located at a functional site.

5: Determine Epitopes. Determination of epitopes can be performed using any  
5 conventional method known in the art, e.g. by use of epitope mapping as described by  
Ivan Roitt in Essential Immunology (Blackwell Scientific Publications, 1994, in particular  
pp. 118-120 thereof) and in the Detailed Description of the Invention section herein.

#### Epitope mapping

10 Several techniques exist for identification of epitopes on a polypeptide of interest (i.e.  
epitope mapping), see, e.g. Romagnoli et al., Biol Chem, 1999, 380(5):553-9, DeLisser  
HM, Methods Mol Biol, 1999, 96:11-20, Van de Water et al., Clin Immunol  
Immunopathol, 1997, 85(3):229-35, Saint-Remy JM, Toxicology, 1997, 119(1):77-81,  
and Lane DP and Stephen CW, Curr Opin Immunol, 1993, 5(2):268-71. One method is to  
15 establish a phage display library expressing random oligopeptides of e.g. 9 amino acid  
residues. IgG1 antibodies from specific antisera towards the polypeptide of interest are  
purified by immunoprecipitation and the reactive phages are identified by  
immunoblotting. By sequencing the DNA of the purified reactive phages, the sequence of  
the oligopeptide can be determined followed by localization of the sequence on the 3D-  
20 structure of the polypeptide of interest. The thereby identified region on the structure  
constitutes an epitope, which then can be selected as a target region for introduction of an  
attachment group for a non-polypeptide moiety or for destruction of the epitope.

#### Assay for Staphylokinase based on a chromogenic assay

25 The principle behind a chromogenic assay is to measure enzymatic activity through an  
enzyme-dependent liberation of a chromophore from a precursor acting as a substrate for  
the enzyme (a chromogenic substrate). As complexes between staphylokinase and  
plasmin act as plasminogen-activators the basis for the chromogenic assay for  
staphylokinase activity is that catalytic amounts of staphylokinase-plasmin complexes  
30 activate plasminogen to plasmin.

In the investigation of plasminogen-activating efficacy of different staphylokinase  
variants, differences in the kinetic behavior of chromophore liberation in this assay will  
reflect differences in the plasminogen-activator activity of different staphylokinase-  
plasmin complexes and thus of the different staphylokinase variants tested.

To conduct the assay, staphylokinase or staphylokinase conjugate is incubated with a small molar excess of plasmin at 37°C. Following the complex-formation period, catalytic amounts of the staphylokinase-plasmin complex is added to plasmin-free plasminogen at 37°C. At well-defined time points aliquots are withdrawn and added to a commercially available chromogenic substrate, e.g. S-2251/H-D-Val-Leu-Lys-pNA for plasmin, and allowed to react for a specified period of time at 37°C. Finally, the colour developed is measured using spectrophotometry. Evaluation of the activation kinetics is carried out by comparison to the colour development found for the relevant reagent and reaction controls.

In this way the formation of plasmin from plasminogen caused by staphylokinase and staphylokinase-polymer conjugate can be followed kinetically. Based upon this it is possible to evaluate the plasminogen-activating efficacy of staphylokinase and conjugates thereof and thus to assess whether or not the staphylokinase conjugate has a measurable function.

15

#### Detection of Antibody Interaction with Conjugated Polypeptide

Immobilized, conjugated polypeptide, such as conjugated staphylokinase, is incubated with antibodies known to react with the non-conjugated polypeptide. The amount of bound antibody is determined using a standard ELISA assay. More specifically, the assay is performed in microtiter plates in which the conjugated polypeptide is covalently attached. The primary antibodies employed can be human antibodies from patients previously exposed to the non-conjugated polypeptide of interest, or polyclonal or monoclonal antibodies raised in animals (e.g. goat, rabbit, mouse, donkey) using the polypeptide of interest in its entirety or peptides sequences from it. Appropriate secondary antibodies conjugated to alkaline phosphatase are used for the detection of the amount of primary antibody bound. The assay is conducted according to the following procedure: Wash coated plate 3X with Wash Buffer (1X PBS (0.058 M Na<sub>2</sub>HPO<sub>4</sub>, 0.017 M NaH<sub>2</sub>PO<sub>4</sub>, 0.068 M NaCl), 0.1% Tween-20).

Block nonspecific binding by incubating wells with Blocking Buffer (0.5% BSA or skimmed milk powder, 0.05% Tween-20 in PBS (0.058 M Na<sub>2</sub>HPO<sub>4</sub>, 0.017 M NaH<sub>2</sub>PO<sub>4</sub>, 0.068 M NaCl).

Wash wells 3X with Wash Buffer.

Dilute primary antibody and test antigen samples in Blocking Buffer and add 100 µl/well. Incubate for at least 1 hour at room temperature with shaking.

Wash wells 3X with Wash Buffer.

Dilute secondary antibody-alkaline phosphatase conjugate in Blocking Buffer and add 100  $\mu$ l/well. Incubate for at least 1 hour with shaking.

Wash wells 4X with Wash Buffer.

- 5 Add standard detectable alkaline phosphatase substrate; incubate for 5-10 min; and measure chemiluminescence at 5 min intervals.

#### PEGylation in microtiter plates of a tagged polypeptide of interest

The method comprises

- 10 expressing the polypeptide of interest with a suitable tag, e.g. any of the tags exemplified in the general description above.

Transferring culture broth to one or more wells in a microtiter plate capable of immobilising the tagged polypeptide. When the tag is His-His-His-His-His-His (Casey et al, J. Immunol. Meth., 179, 105 (1995)), a Ni-NTA HisSorb microtiter plate commercially  
15 available from QiaGen can be used.

After allowing for immobilising the tagged polypeptide to the microtiter plate, the wells are washed in a buffer suitable for binding and subsequent PEGylation.

Incubating the wells with the activated PEG of choice. As an example, M-SPA-5000 from Shearwater Polymers is used. The molar ratio of activated PEG to polypeptide has to be  
20 optimised, but will typically be greater than 10:1 more typically greater than 100:1.

After a suitable reaction time at ambient temperature, typically around 1 hour, the reaction is stopped by removal of the activated PEG solution. The conjugated protein is eluted from the plate by incubation with a suitable buffer. Suitable elution buffers can contain Imidazole, excess NTA or another chelating compound.

- 25 The conjugated protein is assayed for biological activity and immunogenicity as appropriate.

This tag can optionally be cleaved off using a method known in the art, e.g. using diaminopeptidase and the Gln in pos -1 will be converted to pyroglutamyl with GCT (glutamylcyclotransferase) and finally cleaved off with PGAP (pyro-glutamyl-  
30 aminopeptidase) giving the native protein. The process involves several steps of metal chelate affinity chromatography. Alternatively, the tagged polypeptide can be conjugated.

#### EXAMPLE 1

## Cloning and expression of the staphylokinase gene

### *Staphylokinase*

5 Staphylokinase is a single chained polypeptide consisting of 136 amino acid residues without disulfide-bonds and cysteine-residues. The three dimensional structure of staphylokinase has been determined both by x-ray crystallography and by NMR showing that the protein is folded into a single domain (Rabijns *et al.*, Nat. Struct. Biol. 4: 357 (1997); Ohlenschläger *et al.*, Biochemistry: 37 (1998)). In addition, the three dimensional  
10 structure of staphylokinase in complex with  $\mu$ -plasmin has been determined (Parry *et al.*, Nat. Struct. Biol. 5: 917 (1998)).

The B cell epitopes of staphylokinase have recently been mapped using a phage-displayed library of staphylokinase variants selected for mutants that escaped binding to an affinity matrix derivatised with patient-specific polyclonal anti-staphylokinase  
15 antibodies (Jenné *et al.*, J. Immunol. 161: 3161 (1998)). The main B cell epitopes were primarily found in two large discontinuous areas covering 35% of the solvent-accessible surface of staphylokinase.

### *Cloning and expression of the staphylokinase gene*

20 A synthetic gene is constructed on the basis of the so-called SakSTAR gene encoding a *Staphylococcus aureus* staphylokinase variant (SEQ ID NO 3), which as compared to the wildtype *S. aureus* staphylokinase (SEQ ID NO 2) contains the mutation G34S and which codes for a protein having superior thermostability properties (Gase *et al.*, Eur. J. Biochem, 223, 303-308 (1994)). The synthetic gene is constructed with a SalI site at the  
25 5'-end just before the first amino acid codon of the mature staphylokinase and a BamHI at the 3'-end just after the termination codon. The SalI site is designed so the staphylokinase sequence is in frame with the ompT leader sequence of the pET12a expression vector. The synthetic gene is cloned into the SalI site and BamHI site of pET12a, which carries an N-terminal ompT signal sequence for periplasmic export of the staphylokinase. The *E.*  
30 *coli* strains BL21(DE3), B834(DE3), AD494(DE3) or BLR(DE3) are transformed with the resulting vector.

For expression of the staphylokinase, a single colony from one of the transformants is inoculated into LB medium with 50 ug/l ampicillin and grown overnight at 37°C. 2 ml are used to inoculate 50 ml LB medium with 50 ug/l ampicillin and grown

with shaking until OD<sub>600nm</sub> reaches 0.4 to 1.0. Then IPTG is added to a final concentration of 0.4 mM and the incubation is continued for 5 hours at 30°C. The flasks are placed on ice and the cells pelleted by centrifugation. The staphylokinase is purified from the cell supernatant or from the periplasmic fraction of the cells. The periplasmic fraction is  
5 prepared by osmotic shock of the cells.

For large scale preparations the volumes are scaled up.

## EXAMPLE 2

### 10 *Preparing a diversified population of nucleotide sequences encoding staphylokinase modified to increase the number of lysine residues in a target locus of choice*

The sequence of *Staphylococcus aureus* Staphylokinase is available via SwissProt entry SAK\_STAAU accession number P00802. The sequence of the mature protein consists of 136 residues and is shown in SEQ ID NO 2.

15 The three-dimensional X-ray crystallography structure of the C-terminal part (constituting amino acid residues Ser16 to Lys136) of the G34S mutant of the *S. aureus* staphylokinase, which has the amino acid sequence SEQ ID NO 3 and which has superior thermostability properties (Gase et al., *infra*), is used for identifying regions of the staphylokinase which can suitably be modified in their polymer attachment groups. The  
20 strategy for the identification is as described in the "Detailed Disclosure of the Invention" and the "Materials and Methods" section above. The structure (A.Rabijns, H.L.de Bondt, C.de Ranter, "Three-dimensional structure of staphylokinase a plasminogen activator with therapeutic potential" Nat.Struct.Biol. v.4, p.357, (1997)) is available as accession code 2SAK in the PDB (Protein Data Bank) structure depository.

25

### *Determining amino acid residues potentially exposed to the surface:*

The software WHAT IF (see above) was used to determine amino acid residues potentially exposed at the surface of the protein. Using the option *Accessibility* to "Calculate the accessible molecular surface. Output per atom" the following residues  
30 were found to have all of their side chain atoms shielded from the solvent (*i.e* having a zero ASA (accessible surface area), CA for Gly): L25, V27, G31, L55, A67, I87, G110, V113, L127, V131, I133. Accordingly, these are not appropriate targets for mutagenesis. Among the first 15 residues of the sequence, which are not disclosed in the X-ray structure (SSSFDKGKYKKGDDA), F4 and A15 are not hydrophilic amino acid residues



or Gly and thus not expected to be exposed at the surface of the protein. Accordingly, these residues are not considered appropriate targets for mutagenesis.

*Determining the distance from the CB in each residue (in the case of a Gly from the CA) to*  
5 *CB of all lysine residues (only the shortest distance reported).*

From					To					Distance				
										[Å]				
SER	16	LYS	121	14.52	GLU	46	LYS	50	13.82	PHE	47	LYS	59	10.35
TYR	17	LYS	121	18.01	PRO	48	LYS	50	7.42	ILE	49	LYS	50	5.55
PHE	18	LYS	121	13.15	LYS	50	LYS	50	0.00	PRO	51	LYS	50	5.40
GLU	19	LYS	121	9.95	GLY	52	LYS	50	6.36	THR	53	LYS	50	5.57
PRO	20	LYS	121	9.47	THR	54	LYS	59	7.71	LEU	55	LYS	59	5.34
THR	21	LYS	121	7.01	THR	56	LYS	59	4.93	LYS	57	LYS	57	0.00
GLY	22	LYS	121	5.99	GLU	58	LYS	57	5.29	ILE	60	LYS	59	5.35
PRO	23	LYS	50	6.57	LYS	59	LYS	59	0.00	GLU	61	LYS	57	6.49
TYR	24	LYS	50	9.85	THR	62	LYS	59	5.43	TYR	63	LYS	59	6.64
LEU	25	LYS	59	9.55	TYR	63	LYS	59	6.64	VAL	64	LYS	59	10.30
MET	26	LYS	86	13.10	VAL	64	LYS	59	10.30	GLU	65	LYS	74	8.58
VAL	27	LYS	59	11.83	GLU	65	LYS	74	8.58	TRP	66	LYS	74	9.74
ASN	28	LYS	130	10.25	TRP	66	LYS	74	9.74	ALA	67	LYS	74	9.80
VAL	29	LYS	130	7.36	ALA	67	LYS	74	9.80	LEU	68	LYS	74	5.79
THR	30	LYS	130	4.70	LEU	68	LYS	74	5.79	ASP	69	LYS	74	4.50
GLY	31	LYS	130	6.51	ASP	69	LYS	74	4.50	ALA	70	LYS	74	7.46
VAL	32	LYS	130	5.98	ALA	70	LYS	74	7.46	THR	71	LYS	74	6.10
ASP	33	LYS	35	5.55	THR	71	LYS	74	6.10	ALA	72	LYS	74	7.11
SER	34	LYS	35	5.51	ALA	72	LYS	74	7.11	TYR	73	LYS	74	6.05
LYS	35	LYS	35	0.00	TYR	73	LYS	74	6.05	LYS	74	LYS	74	0.00
GLY	36	LYS	35	4.79	LYS	74	LYS	74	0.00	GLU	75	LYS	74	5.38
ASN	37	LYS	35	5.55	GLU	75	LYS	74	5.38	PHE	76	LYS	135	6.10
GLU	38	LYS	130	8.88	PHE	76	LYS	135	6.10	ARG	77	LYS	136	4.91
LEU	39	LYS	35	10.61	ARG	77	LYS	136	4.91	VAL	78	LYS	136	10.57
LEU	40	LYS	130	10.23	VAL	78	LYS	136	10.57	VAL	79	LYS	135	10.55
SER	41	LYS	130	11.49	VAL	79	LYS	135	10.55					
PRO	42	LYS	130	9.59										
HIS	43	LYS	74	11.47										
TYR	44	LYS	130	14.93										
VAL	45	LYS	74	12.47										

GLU	80	LYS	130	9.45	PRO	114	LYS	102	7.45
LEU	81	LYS	130	7.76	ASP	115	LYS	50	9.01
ASP	82	LYS	130	4.70	LEU	116	LYS	102	8.35
PRO	83	LYS	130	10.28	SER	117	LYS	121	5.73
SER	84	LYS	86	7.39	GLU	118	LYS	94	8.83
ALA	85	LYS	86	5.79	HIS	119	LYS	94	6.41
LYS	86	LYS	86	0.00	ILE	120	LYS	121	5.79
ILE	87	LYS	86	5.53	LYS	121	LYS	121	0.00
GLU	88	LYS	86	5.70	ASN	122	LYS	121	4.94
VAL	89	LYS	102	5.15	PRO	123	LYS	121	7.76
THR	90	LYS	102	8.00	GLY	124	LYS	121	10.76
TYR	91	LYS	102	8.50	PHE	125	LYS	102	9.06
TYR	92	LYS	94	6.51	ASN	126	LYS	86	8.94
ASP	93	LYS	96	4.07	LEU	127	LYS	86	8.20
LYS	94	LYS	94	0.00	ILE	128	LYS	130	8.96
ASN	95	LYS	96	5.29	THR	129	LYS	130	5.29
LYS	96	LYS	96	0.00	LYS	130	LYS	130	0.00
LYS	97	LYS	97	0.00	VAL	131	LYS	130	5.83
LYS	98	LYS	98	0.00	VAL	132	LYS	130	7.59
GLU	99	LYS	98	5.46	ILE	133	LYS	135	8.43
GLU	100	LYS	98	6.29	GLU	134	LYS	135	5.41
THR	101	LYS	102	5.84	LYS	135	LYS	135	0.00
LYS	102	LYS	102	0.00	LYS	136	LYS	136	0.00
SER	103	LYS	86	4.51					
PHE	104	LYS	86	6.19					
PRO	105	LYS	86	6.07					
ILE	106	LYS	57	5.24					
THR	107	LYS	109	5.01					
GLU	108	LYS	57	5.27					
LYS	109	LYS	109	0.00					
GLY	110	LYS	109	4.45					
PHE	111	LYS	109	7.84					
VAL	112	LYS	109	10.28					
VAL	113	LYS	50	6.89					

*Determining the distance from the CB in each residue (in the case of a gly from the CA) to the attachment group of all lysines, i.e. the NZ atom of the epsilon amino group of lysine (only the shortest distance reported)*

5	From	To	Distance	From	To	Distance
			[Å]			[Å]


SER	16	LYS	121	15.62	LYS	50	LYS	50	5.03
TYR	17	LYS	121	17.97	PRO	51	LYS	50	5.94
PHE	18	LYS	121	12.76	GLY	52	LYS	50	4.67
GLU	19	LYS	121	10.20	THR	53	LYS	59	5.18
PRO	20	LYS	121	11.82	THR	54	LYS	59	5.80
THR	21	LYS	121	8.23	LEU	55	LYS	59	6.83
GLY	22	LYS	121	9.53	THR	56	LYS	59	7.40
PRO	23	LYS	50	10.64	LYS	57	LYS	57	4.36
TYR	24	LYS	59	14.47	GLU	58	LYS	57	7.11
LEU	25	LYS	59	11.07	LYS	59	LYS	59	5.08
MET	26	LYS	59	16.95	ILE	60	LYS	57	8.34
VAL	27	LYS	59	15.12	GLU	61	LYS	57	6.39
ASN	28	LYS	130	13.01	TYR	62	LYS	59	8.96
VAL	29	LYS	130	11.09	TYR	63	LYS	59	10.04
THR	30	LYS	130	6.31	VAL	64	LYS	57	11.14
GLY	31	LYS	130	8.61	GLU	65	LYS	136	7.52
VAL	32	LYS	130	5.93	TRP	66	LYS	136	11.89
ASP	33	LYS	35	8.21	ALA	67	LYS	74	13.60
SER	34	LYS	35	9.00	LEU	68	LYS	136	9.85
LYS	35	LYS	35	4.18	ASP	69	LYS	136	7.09
GLY	36	LYS	130	6.49	ALA	70	LYS	136	10.29
ASN	37	LYS	35	6.91	THR	71	LYS	136	9.72
GLU	38	LYS	130	7.29	ALA	72	LYS	136	9.18
LEU	39	LYS	135	11.23	TYR	73	LYS	136	9.57
LEU	40	LYS	130	11.70	LYS	74	LYS	136	4.21
SER	41	LYS	130	11.70	GLU	75	LYS	136	5.59
PRO	42	LYS	130	10.81	PHE	76	LYS	136	7.29
HIS	43	LYS	130	14.22	ARG	77	LYS	136	5.58
TYR	44	LYS	130	17.31	VAL	78	LYS	136	8.86
VAL	45	LYS	74	15.86	VAL	79	LYS	57	10.13
GLU	46	LYS	59	16.67	GLU	80	LYS	57	7.02
PHE	47	LYS	59	11.25	LEU	81	LYS	57	6.64
PRO	48	LYS	50	12.33	ASP	82	LYS	130	7.85
ILE	49	LYS	59	8.75	PRO	83	LYS	57	8.48

SER	84	LYS	86	8.96	GLU	118	LYS	96	11.61
ALA	85	LYS	86	9.64	HIS	119	LYS	96	10.07
LYS	86	LYS	86	4.59	ILE	120	LYS	121	8.77
ILE	87	LYS	86	8.47	LYS	121	LYS	121	4.51
GLU	88	LYS	86	8.38	ASN	122	LYS	121	8.09
VAL	89	LYS	102	8.92	PRO	123	LYS	121	11.90
THR	90	LYS	102	9.78	GLY	124	LYS	102	14.43
TYR	91	LYS	102	9.24	PHE	125	LYS	86	13.10
TYR	92	LYS	94	7.41	ASN	126	LYS	86	12.72
ASP	93	LYS	96	5.90	LEU	127	LYS	86	12.54
LYS	94	LYS	94	4.00	ILE	128	LYS	130	11.56
ASN	95	LYS	97	7.21	THR	129	LYS	130	9.32
LYS	96	LYS	96	4.93	LYS	130	LYS	130	4.50
LYS	97	LYS	97	4.43	VAL	131	LYS	130	9.82
LYS	98	LYS	98	4.52	VAL	132	LYS	130	9.62
GLU	99	LYS	98	8.48	ILE	133	LYS	136	10.32
GLU	100	LYS	102	4.79	GLU	134	LYS	135	9.76
THR	101	LYS	102	6.72	LYS	135	LYS	135	4.99
LYS	102	LYS	102	4.51	LYS	136	LYS	136	4.99
SER	103	LYS	86	4.25					
PHE	104	LYS	86	6.39					
PRO	105	LYS	86	4.68					
ILE	106	LYS	57	7.56					
THR	107	LYS	57	8.64					
GLU	108	LYS	57	7.47					
LYS	109	LYS	109	4.35					
GLY	110	LYS	109	6.98					
PHE	111	LYS	109	8.70					
VAL	112	LYS	109	8.85					
VAL	113	LYS	50	8.67					
PRO	114	LYS	102	9.57					
ASP	115	LYS	50	8.88					
LEU	116	LYS	102	9.78					
SER	117	LYS	121	9.09					

*Determining the shortest distance from the attachment group (NZ) of each of the lysine residues to the attachment group (NZ) of the closest other the lysine groups.*

From		To		Distance [Å]
LYS	35	LYS	130	14.54
LYS	50	LYS	59	10.70
LYS	57	LYS	59	15.39
LYS	59	LYS	50	10.70
LYS	74	LYS	136	9.64
LYS	86	LYS	102	11.47
LYS	94	LYS	97	3.66
LYS	96	LYS	102	6.94
LYS	97	LYS	94	3.66
LYS	98	LYS	96	8.99
LYS	102	LYS	96	6.94
LYS	109	LYS	59	13.84
LYS	121	LYS	94	14.05
LYS	130	LYS	35	14.54
LYS	135	LYS	74	11.98
LYS	136	LYS	74	9.64

5

*Determining residues located at the functional site*

Based on the X-ray structure of the ternary complex of microplasmin-staphylokinase-microplasmin (Parry *et.al.* Nature Structural Biology, 1998, 5: 917-923) the following residues are potentially involved in staphylokinase's action. These are: E19, Y24, M26, N28, E38, S41, H43, Y44, E46, F47, P48, Y62, W66, A70, Y73, E75.

10

*Determining main epitopes of Staphylokinase*

Jenné *et.al.* *The journal of Immunology*, 1998, 161: 3161-3168. have determined the major B Cell epitopes of Staphylokinase in Humans. The result was 25 residue positions considered as critical for recognition of Staphylokinase (Sak) by polyclonal anti-Sak IgG's: K6, K8, S16, E19, T21, W66, D69, A72, Y73, K74, E75, F76, K94, N95, K96, K97, E99, K102, S103, K109, E118, K121, K130, K135, K136.

*Selection of residues to be mutagenized to a residue having a polymer attachment group (exemplified by lysine)*

10

Residues to be mutagenized to a lysine residue can be summarized as:

A) Residues potentially on the surface and not already lysine residues or N-terminal: S2, S3, D5, G7, Y9, G12, D13, D14, S16, Y17, F18, E19, P20, T21, G22, P23, Y24, M26, N28, V29, T30, V32, D33, S34, G36, N37, E38, L39, L40, S41, P42, H43, Y44, V45, E46, F47, P48, I49, P51, G52, T53, T54, T56, E58, I60, E61, Y62, Y63, V64, E65, W66, L68, D69, A70, T71, A72, Y73, E75, F76, R77, V78, V79, E80, L81, D82, P83, S84, A85, E88, V89, T90, Y91, Y92, D93, N95, E99, E100, T101, S103, F104, P105, I106, T107, E108, F111, V112, P114, D115, L116, S117, E118, H119, I120, N122, P123, G124, F125, N126, I128, T129, V132, E134.

20

B) Residues where the mutation is conservative: R77K

C) Residues having their CB (or in the case of a gly CA) at a distance of more than 8 Å from the CB of the nearest Lys residue: S16, Y17, F18, E19, P20, Y24, M26, N28, E38, L39, L40, S41, P42, H43, Y44, V45, E46, F47, V64, E65, W66, V78, V79, E80, P83, T90, Y91, V112, D115, L116, E118, G124, F125, N126, I128.

25

C) Residues having their CB (or in the case of a gly CA) at a distance of more than 10 Å from the CB of the nearest Lys residue: S16, Y17, F18, M26, N28, L39, L40, S41, H43, Y44, V45, E46, F47, V64, V78, V79, P83, V112, G124.

30



D) Residues having their CB (or in the case of a gly CA) at a distance of more than 10 Å from the NZ of the nearest Lys residue: S16, Y17, F18, E19, P20, P23, Y24, M26, N28, V29, L39, L40, S41, P42, H43, Y44, V45, E46, F47, P48, Y63, V64, W66, A70, V79,  
5 E118, H119, P123, G124, F125, N126, I128.

E) Residues in a known epitope region: S16, E19, T21, W66, D69, A72, Y73, E75, F76, N95, E99, S103, E118.

10 F) Residues which are not located at the functional site: S2, S3, D5, G7, Y9, G12, D13, D14, S16, Y17, F18, P20, T21, G22, P23, V29, T30, V32, D33, S34, G36, N37, L39, L40, P42, V45, I49, P51, G52, T53, T54, T56, E58, I60, E61, Y63, V64, E65, L68, D69, T71, A72, F76, R77, V78, V79, E80, L81, D82, P83, S84, A85, E88, V89, T90, Y91, Y92, D93, N95, E99, E100, T101, S103, F104, P105, I106, T107, E108, F111, V112, P114,  
15 D115, L116, S117, E118, H119, I120, N122, P123, G124, F125, N126, I128, T129, V132, E134.

Based on the above considerations regions including amino acid residues 16-18 and 124-128 are chosen for being subjected to localized or focused mutagenesis towards  
20 introduction of lysine residues.

*Focused mutagenesis towards introduction of lysine residues*

The below primers are used to introduce one lysine residue, at random, into each of the two regions constituting amino acid residues 16 to 18 and amino acid residues 124 to 128,  
25 respectively. The primers with the number 2 contain an Eco RI cloning site.

The primers are mixed in equimolar amounts and used in a PCR reaction. The resulting PCR product is used in a second PCR reaction with an upstream primer containing a proper cloning site in order to clone the product in a proper expression vector such as pET12a.

30

Primer 1a (S16K):

5' AAA AAG GGC GAT GAC GCG AAG TAT TTT GAA CCA ACA GGC CCG 3'  
(SEQ ID NO 4)

Primer 1b (Y17K):

5 5' AAA AAG GGC GAT GAC GCG AGT AAG TTT GAA CCA ACA GGC CCG 3'  
(SEQ ID NO 5)

Primer 1c (F18K):

5' AAA AAG GGC GAT GAC GCG AGT TAT AAG GAA CCA ACA GGC CCG 3'  
10 (SEQ ID NO 6)

Primer 1d (wt):

5' AAA AAG GGC GAT GAC GCG AGT TAT TTT GAA CCA ACA GGC CCG 3'  
(SEQ ID NO 7)

15

Primer 2a (G124K):

5' CGGAATTC TTA TTT CTT TTC TAT AAC AAC CTT TGT AAT TAA GTT GAA  
CTT AGG GTT TTT AAT ATG C 3' (SEQ ID NO 8)

20 Primer 2b (F125K):

5' CGGAATTC TTA TTT CTT TTC TAT AAC AAC CTT TGT AAT TAA GTT CTT  
TCC AGG GTT TTT AAT ATG C 3' (SEQ ID NO 9)

Primer 2c (N126K):

25 5' CGGAATTC TTA TTT CTT TTC TAT AAC AAC CTT TGT AAT TAA CTT GAA  
TCC AGG GTT TTT AAT ATG C 3' (SEQ ID NO 10)

Primer 2d (I128K):

5' CGGAATTC TTA TTT CTT TTC TAT AAC AAC CTT TGT CTT TAA GTT GAA  
30 TCC AGG GTT TTT AAT ATG C 3' (SEQ ID NO 11)

Primer 2e (wt):

5' CGGAATTC TTA TTT CTT TTC TAT AAC AAC CTT TGT AAT TAA GTT GAA  
TCC AGG GTT TTT AAT ATG C 3' (SEQ ID NO 12)

- 5 Subsequently, the resulting mutated nucleotide sequences are introduced into pET12a and transformed into *E. coli* as described in Example 1. A small aliquot of the transformation mixture is plated on agar plates (LB medium containing ampicilin) and the rest is frozen at  $-80^{\circ}\text{C}$ . The next day the transformation frequency is determined and the frozen transformation mixture is diluted so as to obtain growth in 70% of the wells when 200
- 10 mikroliters of the transformation mixture is loaded into each well of a 96-well microtiter plate. The microtiter plate is fermented until optimal expression is achieved (normally for about three days) at  $30^{\circ}\text{C}$ . Then, 20 mikroliters of the supernatant from each well is transferred to the screening plate and subjected to screening as described in Example 5.

### 15 EXAMPLE 3

*Localized mutagenesis to remove amino acid residues containing an attachment group*

The criteria for the selections of suitable regions for localized mutagenesis include the following:

20

A) The mutation should preferably be of a conservative type.

- B) Regions containing amino acid residues containing a polymer attachment group which are located close in space and/or close in sequence are target for mutagenesis. For instance,
- 25 if such residues are separated by less than three amino acid residues in the primary sequence and/or having their attachment groups are separated by less than  $10 \text{ \AA}$ , preferably  $8 \text{ \AA}$  more preferably  $5 \text{ \AA}$  the surrounding region is a target for mutagenesis.

On the basis of the above considerations and the data provided in the tables above regions including the following lysine residues are targets for mutagenesis aiming at removing and

30 thus reducing the number of lysine residues:

K74, K94, K96, K97, K98, K102, K136 (being less than 10Å from the attachment group of the closest other lysine residue), preferably K94, K96, K97, K102 (being less than 8Å from the attachment group of the closest other lysine residue), and most preferably K94, K97 (being less than 5Å from the closest other lysine residue).

5           The below primer 3 is designed to remove selected lysine residues from position K94, K96, K97 and K102. The primer contains an Eco47 III (or Hae II) cloning site at the 5'-end (underlined). The Ala85 codon has been changed from GCA to GCT. The primer 4 contains a Eco RI site for cloning.

10           The primers are mixed in equimolar amounts and used in a PCR reaction. The resulting PCR product can be cloned into a proper expression vector after digestion with Eco 47 III and Eco RI.

Primer 3 (K94X, K96X, K97X, K102X):

5' CCA AGC GCT AAG ATC GAA GTC ACT TAT TAT GAT 556 AAT 556 556 AAA  
15 GAA GAA ACG 556 TCT TTC CCT ATA ACA GAA AAA 3' (SEQ ID NO 13)

Bottle 5: 70% A, 10% G, 10% C, 10% T

Bottle 6: 90% G, 10% C

20   Primer 4:

5' CGGAATTC TTA TTT CTT TTC TAT AAC AAC 3' (SEQ ID NO 14)

Subsequently, the resulting mutated nucleotide sequences are introduced into pET12a and expressed in *E. coli* as described in Example 1.

25

#### EXAMPLE 4

PEGylation of the diversified population of nucleotide sequences prepared as described in  
30   Example 2 and 3

Fermentation broth originating from expression in microtiter plates of the staphylokinase random mutagenesis library is transferred to a microtiter plate where each well is coated with suitable amounts of human plasmin or plasminogen and subsequently residual binding capacity blocked by BSA. Prior to addition of the fermentation broth, the plasmin or plasminogen coated microtiter wells are washed in suitable buffer, e.g. the buffer used to carry out the PEGylation step.

PEGylation is done in accordance to manufacturer's instructions. It is essential that an excess amount of activated PEG is used in order to ensure proper PEGylation of the staphylokinase. In this connection, the amount of activated PEG required reacting with the attachment groups on plasmin and BSA is to be taken into account. An alternative to BSA such as Tween 80 can be used to achieve blocking of binding capacity in the microtiter well.

PEGylation with Succinimidyl Propionate PEG is performed in accordance with methods known in the art. Monosubstituted PEG with an average molecular weight of 2000 is used (available from Shearwater, Inc., Huntsville, Alabama) and PEGylation done according to the manufacturer's instructions. When PEGylation is carried out in microtiter plates all concentrations of ingredients are used as according to the manufacturer's instructions, only volumes are scaled down. For instance, during conjugation in a 96-well microtiter plate a final volume of approx. 200 mikroliters are used per well.

## EXAMPLE 5

### Screening and selection of improved PEGylated staphylokinase variants

#### *Efficacy assay:*

The efficacy of PEGylated staphylokinase variants resulting from Example 4 is analysed by the chromogenic assay described above in the Materials and Methods section. The principle is that staphylokinase in complex with plasmin activates plasminogen to plasmin. Plasmin liberates a chromophore from commercially available chromogenic substrates for plasmin e.g. S-2251 from Chromogenix. Differences in the kinetic behavior in this assay reflects the variants' and the PEGylated variants' plasminogen-activating efficacy. The

efficacy of the PEGylated variants is assayed in microtiterplates according to the method described in the Materials and Methods section herein.

*Immunological assay:*

- 5 Immunological assays are conducted using the method described in the Materials and Methods section.

EXAMPLE 6

10

Purification and characterization of PEGylated staphylokinase variants

- A DNA sequence encoding the polypeptide part of the staphylokinase-PE conjugate selected as described in Example 5 is isolated and used for recombinant production of larger amounts of said polypeptide part using the expression system described in Example 1. Subsequently, the resulting polypeptides are purified (as described below) and subjected to PEGylation as described in Example 4.

- To ease purification of the relatively large number of variants the commercially available system called TagZyme is used. Briefly described it requires that the protein is expressed with a His15-tag that facilitates binding to an Immobilised metal-ion Affinity Chromatography (IMAC) matrix (e.g. a Zn-chelate matrix). Following the initial purification of His15-tagged staphylokinase variants employing IMAC, the His15-tag is cleaved off with a His15-tagged diamino peptidase. Subsequently, the His15-tagged diamino peptidase (as well as other contaminants) is removed from the staphylokinase variants using subtractive IMAC. Alternatively, standard purification schemes known from the literature will be employed.

- Before PEGylation is carried out on the purified staphylokinase variants the following characterization is done.
- SDS-PAGE (Coomassie BB stained) for purity,
- 30 LAL-test for endotoxins,

Mass spectrometry and amino acid sequencing for identity and to confirm that the expected changes are present, and

Amino acid analysis for concentration determination.

5           Following the PEGylation of purified staphylokinase variant the surplus of reagents is removed through a final gelfiltration.

          The purified PEGylated staphylokinase variants are analysed and characterized by SDS-PAGE for size heterogeneity, IEF for charge heterogeneity, Analysis of degree of PEGylation, e.g. by assaying the conjugate with trinitrobenzene sulfonic acid (TNBS) to  
10   determine the number of free amino groups, analytical size exclusion HPLC with light scattering detection, analytical an-ion, cat-ion, or hydrophobic interaction chromatography, amino acid analysis for concentration determination, peptide mapping and mass spectrometry and amino acid sequencing of resulting peptides.

## 15   EXAMPLE 7

### Introduction of glycosylation sites in staphylokinase

In *Staphylococcus aureus* staphylokinase having the amino acid sequence shown in SEQ ID NO 2 the following mutations Xxx-Asn placed at positions potentially exposed to the  
20   surface at sequence positions located two residues prior to a Ser or a Thr and not at the N-terminal position and not containing a Pro at the “middle” position introduce a potential N-glycosylation site: D14N, L39N, P51N, G52N, T54N, D69N, E88N, E99N, T101N, P105N and/or D115N. Most preferably, the mutations to be used for introducing an N-glycosylation site are D14N, D69N and/or D115N.

25   Similar in the *Staphylococcus aureus* staphylokinase the following mutations Xxx-Ser or Xxx-Thr placed at amino acid residues located two residues after a potential surface exposed Asn residue and not just after a Pro residue introduce a potential N-glycosylation site: L39S, K97S, I128S, L39T, K97T and/or I129T.

          The mutations are introduced by site-directed or random mutagenesis by use of  
30   conventional methods known in the art. For expression of the protein of interest in *S. cerevisiae* a plasmid shuttle vector based on the pYES vectors (InVitrogen Inc.) can be

used. For instance the published expression vector pJSO37 (Okkels, Ann. New York Acad. Sci. 782, 202-207, 1996) is used for expression of the staphylokinase by cloning the gene encoding the mature part of the staphylokinase in frame and just downstream of the signal peptide of the lipase gene (present in pJSO37). The staphylokinase variants will then be glycosylated in the *S. cerevisiae* cell and secreted.

## EXAMPLE 8

### Random alteration of glycosylation pattern

In many therapeutic applications it is desirable to alter the immunogenicity or functional *in vivo* or serum half-life of an administered polypeptide or protein therapeutic agent. In many cases, it is preferable to administer a protein with reduced immunogenic potential to prevent or reduce an immune response against the agent which results in neutralization or elimination of the agent, or in immune mediated side effects, including cell or tissue damage and anaphylaxis. Alterations in the glycosylation pattern of a polypeptide influences immunogenicity in at least two important ways. Firstly, many antibodies recognize epitopes present on the glycosylated form of proteins. Secondly, glycosylation can influence processing of an antigenic protein, and or mask certain antigenic epitopes of a polypeptide.

To produce a target protein therapeutic agent with reduced immunogenicity, a library of target protein variants, or subportions thereof, is produced by any combination of the mutagenesis methods described herein. For example, random mutagenesis is favorably employed in cases where little is known regarding the presence, and location of antigenic regions of the protein. Focused mutagenesis, employing spiking mixtures enriched for nucleotide sequences likely to encode N- or O- glycosylation sites, e.g., that encode asparagine, serine, or threonine residues, is also desirable in this context. In cases where epitope mapping has indicated particular regions of the protein contributing to a 1° or 3° structure comprising an epitope, localized mutagenesis is favorably utilized. The library is then screened to assess immunogenicity, half-life, or other desirable properties, of the protein variants. For example, the ability of variants to elicit a lymphoproliferative response in cells specific for the target protein is assayed *in vitro* by



measuring  $^3\text{H}$ -thymidine uptake. Alternatively, antibody binding can be quantitated. Confirmation of a reduction in immunogenicity can be achieved by immunizing an experimental organism, e.g., a mouse, and assessing the resulting immune response by techniques well established in the art (*see*, e.g., Current Protocols in Immunology (1991)

5 Coligan et al. (eds) John Wiley and Sons, New York).

In other cases, the library is screened for variants that exhibit an increased ability to elicit an immune response. Such protein variants can be valuable reagents in the production of specific antibodies for experimental and therapeutic purposes.

Alternatively, target proteins with altered immunogenicity that have a reduced ability to  
10 elicit one aspect of an immune response, e.g., IgE secretion, while maintaining the capacity to evoke another aspect of a specific immune response, e.g., IgG secretion, can be identified among the variants of the library. Such proteins are useful, e.g., in producing desensitization to a specific allergen corresponding to the target protein.

While the foregoing invention has been described in some detail for purposes of  
15 clarity and understanding, it will be clear to one skilled in the art from a reading of this disclosure that various changes in form and detail can be made without departing from the true scope of the invention. For example, all the techniques and apparatus described above may be used in various combinations. All publications and patent documents cited in this application are incorporated by reference in their entirety for all purposes to the same  
20 extent as if each individual publication or patent document were individually so denoted.